<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0">
    <channel>
        <title>Oral Oncology via MedWorm.com</title>
        <description>MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Oral Oncology' source.</description>
        <link><![CDATA[http://www.medworm.com/rss/search.php?qu=Oral+Oncology&t=Oral+Oncology&s=Search&f=source]]></link>
        <lastBuildDate>Wed, 08 Feb 2012 08:41:53 +0100</lastBuildDate>
        <item>
            <title>Editorial Board/Aims &amp; Scope</title>
            <link>http://www.medworm.com/index.php?rid=5638236&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511009341%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: Oral Oncology)</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5638236</comments>
            <pubDate>Sun, 29 Jan 2012 13:24:38 +0100</pubDate>
            <guid isPermaLink="false">5638236</guid>        </item>
        <item>
            <title>Psychological functioning of caregivers for head and neck cancer patients</title>
            <link>http://www.medworm.com/index.php?rid=5597072&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511009018%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Patients with head and neck squamous cell carcinoma (HNSCC) often require assistance from family caregivers during the treatment and post-treatment period. This review article sought to summarize current findings regarding the psychological health of HNSCC caregivers, including factors that may be associated with poorer psychological health. Online databases (PUBMED, MEDLINE and PSYCINFO) were searched for papers published in English through September 2010 reporting on the psychological health of caregivers of HNSCC patients. Eleven papers were identified. Caregivers experience poorer psychological health, including higher levels of anxious symptoms, compared to patients and to the general population. Fear of patient cancer recurrence is evident among caregivers and is associated ...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5597072</comments>
            <pubDate>Mon, 12 Dec 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5597072</guid>        </item>
        <item>
            <title>Accuracy of MRI in prediction of tumour thickness and nodal stage in oral squamous cell carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=5638246&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511008815%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: We aim to compare radiological with histological tumour thickness (RTT with HTT) for oral squamous cell carcinoma (OSCC), and the ability of both to predict cervical metastasis. The MRI images and histopathology reports of 102 consecutive OSCC cases were compared and therelationship between RTT and HTT, calculated as a “shrinkage factor” by the gradient of the best fitting regression line. Most (69%) tumours appeared thicker on MRI than was revealed by histopathology. Shrinkage factor was 0.70 (interquartile range 0.63–0.77, correlation co-efficient 0.63) for all cases, 0.87 (IQR 0.80–0.95, CC 0.88) for tongue and 0.65 (IQR 0.49–0.82, CC 0.45) for floor of mouth sub-sites. RTT did not correlate well with the presence of nodal metastases in any sub-site, i.e. there was no...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5638246</comments>
            <pubDate>Fri, 09 Dec 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5638246</guid>        </item>
        <item>
            <title>Retraction notice to “Nef from SIVmac239 decreases proliferation and migration of adenoid-cystic carcinoma cells and inhibits angiogenesis” [OO 47 (2011) 847–854]</title>
            <link>http://www.medworm.com/index.php?rid=5597084&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511009006%2Fabstract%3Frss%3Dyes</link>
            <description>This article has been retracted: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy).  This paper has been retracted at the request of the Editors of Oral Oncology and the authors of the paper. (Source: Oral Oncology)</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5597084</comments>
            <pubDate>Fri, 02 Dec 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5597084</guid>        </item>
        <item>
            <title>Methylation of microRNA-9 is a specific and sensitive biomarker for oral and oropharyngeal squamous cell carcinomas</title>
            <link>http://www.medworm.com/index.php?rid=5597080&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511008852%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Detection of DNA methylation has produced promising results as biomarkers for head and neck squamous cell carcinoma (HNSCC). However, current panels are limited by an insufficient number of sensitive and specific tumor markers. MicroRNAs (miR) play an important role in tumorigenesis, and may represent a novel panel of molecules for the development of cancer biomarkers. We investigated methylation of three miRNA promoter sites of miR-9 (miR-9-1, miR-9-2, miR-9-3) in 107 human head and neck tissue samples and controls. We found methylations of miR-9-1 and miR-9-3 were higher in oral and oropharyngeal carcinomas than that in laryngeal carcinoma, achieving a combined sensitivity of 63% and 56%, respectively, for these two tumor types, compared to 21% for the laryngeal carcinoma. Quant...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5597080</comments>
            <pubDate>Fri, 02 Dec 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5597080</guid>        </item>
        <item>
            <title>Editorial Board/Aims &amp; Scope</title>
            <link>http://www.medworm.com/index.php?rid=5457149&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS136883751100889X%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: Oral Oncology)</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5457149</comments>
            <pubDate>Thu, 01 Dec 2011 01:56:25 +0100</pubDate>
            <guid isPermaLink="false">5457149</guid>        </item>
        <item>
            <title>The biology of head and neck cancer stem cells</title>
            <link>http://www.medworm.com/index.php?rid=5597070&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511008591%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Emerging evidence indicates that a small population of cancer cells is highly tumorigenic, endowed with self-renewal, and has the ability to differentiate into cells that constitute the bulk of tumors. These cells are considered the “drivers” of the tumorigenic process in some tumor types, and have been named cancer stem cells. Epithelial-mesenchymal transition (EMT) appears to be involved in the process leading to the acquisition of stemness by epithelial tumor cells. Through this process, cells acquire an invasive phenotype that may contribute to tumor recurrence and metastasis. Cancer stem cells have been identified in human head and neck squamous cell carcinomas (HNSCC) using markers such as CD133 and CD44 expression, and aldehyde dehydrogenase (ALDH) activity. The head an...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5597070</comments>
            <pubDate>Wed, 09 Nov 2011 05:00:00 +0100</pubDate>
            <guid isPermaLink="false">5597070</guid>        </item>
        <item>
            <title>Vesicular stomatitis virus matrix protein (VSVMP) inhibits the cell growth and tumor angiogenesis in oral squamous cell carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=5638239&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511008220%2Fabstract%3Frss%3Dyes</link>
            <description>This study indicated that VSVMP treatment can effectively inhibited the cell growth and tumor angiogenesis in OSCC without obvious adverse effects. Therefore, VSVMP might be a potential and efficient strategy for OSCC treatment. (Source: Oral Oncology)</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5638239</comments>
            <pubDate>Fri, 28 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5638239</guid>        </item>
        <item>
            <title>HNOCDB: A comprehensive database of genes and miRNAs relevant to head and neck and oral cancer</title>
            <link>http://www.medworm.com/index.php?rid=5638240&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511008396%2Fabstract%3Frss%3Dyes</link>
            <description>We present HNOCDB, the head, neck and oral cancer database, with the following key features: (i) it tabulates all the different categories of HNOC separately under appropriate subtype-names, and then puts them together in a table headlined All; (ii) the oncogenes/oncomiRs that cause HNOC are listed; their mutations, methylations and polymorphisms loci are marked, and the variations in their expression profiles relative to the normal are recorded; (iii) HNOCDB contains a chromosomal map of HNOC genes and miRNA; (iv) contains references that experimentally validate the reason for the inclusion of the genes and the miRNAs in HNOCDB. HNOCDB is freely accessible for academic and non-profit users via http://gyanxet.com/hno.html. (Source: Oral Oncology)</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5638240</comments>
            <pubDate>Mon, 24 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5638240</guid>        </item>
        <item>
            <title>Therapeutic targets in head and neck squamous cell carcinoma: Identification, evaluation, and clinical translation</title>
            <link>http://www.medworm.com/index.php?rid=5597071&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511008384%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Head and neck squamous cell carcinoma (HNSCC) encompasses a diverse group of malignancies originating in the oral cavity, oropharynx, larynx and hypopharynx. Although treatment modalities have improved, carefully designed biomarker-driven clinical trials will yield the best opportunities to enhance HNSCC therapy options in the future. Due to the heterogeneous nature of HNSCC, discovering a “silver bullet” for the treatment of HNSCC is unlikely. Consequently, impactful HNSCC clinical trials will require multiple assay platforms and expanded technical expertise. In this review, we will outline pathways critical to HNSCC oncogenesis and highlight signaling nodes within these pathways that represent biomarkers for prognosis and potential targeted therapies. All treatment modalitie...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5597071</comments>
            <pubDate>Mon, 24 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5597071</guid>        </item>
        <item>
            <title>Editorial Board/Aims &amp; Scope</title>
            <link>http://www.medworm.com/index.php?rid=5335288&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511008505%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: Oral Oncology)</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5335288</comments>
            <pubDate>Sat, 22 Oct 2011 00:59:22 +0100</pubDate>
            <guid isPermaLink="false">5335288</guid>        </item>
        <item>
            <title>Head and neck inflammatory myofibroblastic tumor (IMT): Evaluation of clinicopathologic and prognostic features</title>
            <link>http://www.medworm.com/index.php?rid=5638245&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511008190%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Owing to rarity and awareness deficiency towards inflammatory myofibroblastic tumor (IMT), we sought to review on its clinicopathological features; arising awareness to achieve early diagnosis; exploring prognostic factors and then establishing a treatment protocol. Retrospective study was performed on patients with histological proven IMT between January 2003 and December 2010. Their demographic data, clinical and histological presentations were recorded. Overall survival (OS) and progression-free-survival (PFS) were estimated via Kaplan–Meier method. Cox regression model was applied to determine the significant of prognostic factors. Logistic regression model was established to predict the probability of relapse. A total of 28 patients. Five-year PFS was 65%. Surgical margins ...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5638245</comments>
            <pubDate>Wed, 19 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5638245</guid>        </item>
        <item>
            <title>Endothelial derived factors inhibit anoikis of head and neck cancer stem cells</title>
            <link>http://www.medworm.com/index.php?rid=5597073&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511008256%2Fabstract%3Frss%3Dyes</link>
            <description>This study revealed that endothelial cells initiate a crosstalk that protect head and neck cancer stem cells against anoikis, and suggest that therapeutic interference with this crosstalk might be beneficial for patients with head and neck cancer. (Source: Oral Oncology)</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5597073</comments>
            <pubDate>Wed, 19 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5597073</guid>        </item>
        <item>
            <title>Impact of smoking status on clinical outcome in oral cavity cancer patients</title>
            <link>http://www.medworm.com/index.php?rid=5638252&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS136883751100827X%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: The association between smoking status and survival in oral cavity squamous cell carcinoma (OSCC) patients remains unclear. Therefore, we evaluated the association between smoking status before treatment and clinical outcome in OSCC patients. We conducted a retrospective cohort study of 222 OSCC patients who were treated at Aichi Cancer Center in Japan. Of these, 82 patients (36.9%) were non-smokers, 65 (29.3%) were light smokers (pack-years smoking (PY) (Source: Oral Oncology)</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5638252</comments>
            <pubDate>Thu, 13 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5638252</guid>        </item>
        <item>
            <title>In vitro influence of the extracellular matrix in myoepithelial cells stimulated by malignant conditioned medium</title>
            <link>http://www.medworm.com/index.php?rid=5638238&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511008232%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: In order to investigate the role of myoepithelial cell and tumor microenvironment in salivary gland neoplasma, we have performed a study towards the effect of different extracellular matrix proteins (basement membrane matrix, type I collagen and fibronectin) on morphology and differentiation of benign myoepithelial cells from pleomorphic adenoma cultured with malignant cell culture medium from squamous cell carcinoma. We have also analyzed the expression of α-smooth muscle actin (α-SMA) and FGF-2 by immunofluorescence and qPCR. Our immunofluorescence results, supported by qPCR analysis, demonstrated that α-SMA and FGF-2 were upregulated in the benign myoepithelial cells from pleomorphic adenoma in all studied conditions on fibronectin substratum. However, the myoepithelial cell...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5638238</comments>
            <pubDate>Thu, 13 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5638238</guid>        </item>
        <item>
            <title>Is neck dissection needed in squamous-cell carcinoma of the maxillary gingiva, alveolus, and hard palate? A multicentre Italian study of 65 cases and literature review</title>
            <link>http://www.medworm.com/index.php?rid=5638237&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007998%2Fabstract%3Frss%3Dyes</link>
            <description>We present a retrospective multicentre study of 65 patients with squamous-cell carcinomas of the maxillary alveolar ridge and hard palate and review of the existing literature.The overall incidence of cervical metastases was 21%. We evaluated the significance of primary-site tumours as indicator of regional disease.The maxillary squamous-cell carcinoma cases in our multicentre study and in the literature review exhibited aggressive regional metastatic behaviour, comparable with that of carcinomas of the tongue, mouth floor, and mandibular gingiva. Based on our findings, we recommend selective neck dissection in clinically negative necks as a primary management strategy for patients with maxillary squamous-cell carcinomas involving the palate, maxillary gingiva, or maxillary alveolus. (Sour...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5638237</comments>
            <pubDate>Wed, 12 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5638237</guid>        </item>
        <item>
            <title>Tumor induced osteomalacia: A forgotten paraneoplastic syndrome?</title>
            <link>http://www.medworm.com/index.php?rid=5638257&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511008268%2Fabstract%3Frss%3Dyes</link>
            <description>Paraneoplastic syndromes are disorders that accompany benign or malignant tumors but are not directly related either to mass effect or to invasiveness of the tumor (primary or metastatic), nor are they associated with side-effects of anti-cancer treatment. They instead represent either the endocrinologic, hematologic, dermatologic and neurologic manifestations of ectopic hormone production by a tumor, or the immunological responses to the tumor. Recently, Toro et al. Chapireau et al. and Feller et al. separately reviewed the paraneoplastic syndromes related to oral neoplasms including, among others, hypercalcaemia, hypercalcaemia–leukocytosis syndrome, syndrome of inappropriate antidiuretic hormone production, ectopic production of beta-human chorionic gonadotrophin, Bazex syndrome, Swee...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5638257</comments>
            <pubDate>Mon, 10 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5638257</guid>        </item>
        <item>
            <title>Oncocytic mucoepidermoid carcinoma with prominent tumour-associated lymphoid proliferation of the submandibular gland</title>
            <link>http://www.medworm.com/index.php?rid=5638256&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511008244%2Fabstract%3Frss%3Dyes</link>
            <description>We report a peculiar oncocytic mucoepidermoid carcinoma (OMEC) with the unusually prominent lymphoplasmacytic component occurring in the submandibular gland.  A 70-year-old male patient presented with a painless mass in the right submandibular region. Magnetic resonance imaging revealed a well-defined and heterogeneously enhancing mass that measured approximately 2.0cm in diameter in the right submandibular gland. A core-cut biopsy was performed, which allowed for a diagnosis of OMEC. The patient underwent total excision of the right submandibular gland. He recovered fully and was free of disease at the 19-month follow-up. (Source: Oral Oncology)</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5638256</comments>
            <pubDate>Wed, 05 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5638256</guid>        </item>
        <item>
            <title>Impact of elective neck dissection on regional recurrence and survival in cN0 staged oral maxillary squamous cell carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=5638250&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511008219%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: To evaluate the impact of elective neck dissection (END) on regional recurrence and survival in cN0 staged patients with maxillary squamous cell carcinoma (SCC).Eighty-six patients with maxillary SCC and clinically staged N0 cervical lymph-nodes were evaluated in this single center retrospective study.Seventy-four of 86 patients were included in this analysis, of which 36 patients were treated with END, 38 without END. Following END, pathohistologically verified regional lymph-nodes in the initially cN0 neck were found in three (8%) patients. In both the +END and non-END group regional recurrences occurred exclusively in patients with T4 primaries. The overall regional recurrence rate was 17% in the +END and 18% in the non-END group, respectively. The 5-year overall survival rate ...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5638250</comments>
            <pubDate>Wed, 05 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5638250</guid>        </item>
        <item>
            <title>Salivary gland carcinoma in Denmark 1990–2005: Outcome and prognostic factors: Results of the Danish Head and Neck Cancer Group (DAHANCA)</title>
            <link>http://www.medworm.com/index.php?rid=5638251&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511008207%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: To describe outcome and prognostic factors in a national Danish series of patients treated for salivary gland carcinoma. From three Danish nation-wide registries and supplementary patient records, 871 patients diagnosed with primary major or minor salivary gland carcinoma in the period from 1990 to 2005 were identified. A total of 796 (91%) histological specimens were revised according to the WHO 2005 classification. The median follow-up time was 78months. Three hundred and thirty-four patients (38%) experienced recurrence. Crude survival, disease-specific survival and recurrence-free survival after 5 and 10years were 66%, 76%, 64% and 51%, 69%, 58%, respectively. In multivariate analysis age, latency, stage, microscopic margins, vascular invasion and histological grade were all i...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5638251</comments>
            <pubDate>Tue, 04 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5638251</guid>        </item>
        <item>
            <title>The anti-tumour effect of cisplatin and ifosfamide on xenografted squamous cell carcinoma of the head and neck is schedule-dependent</title>
            <link>http://www.medworm.com/index.php?rid=5597078&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511008189%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: The role of chemotherapy (CHX) in squamous cell carcinoma of the head and neck (SCCHN) has been expanding. Although combination chemotherapy regimens regularly produce significantly high response rates, meta-analyses show little benefit regarding final outcome. One way to improve induction CHX is to improve drug combinations and schedules for CHX. Cisplatin (CDDP) is one of the most active drugs in the treatment of patients with SCCHN, and it is used in most combinations. Ifosfamide (IFO) is another agent that has shown activity in the treatment of patients with SCCHN. A poorly differentiated squamous cell carcinoma xenografted to nude mice was used. CDDP (2.5mg/kg) and IFO (100mg/kg) as single bolus doses induced significant retardation of tumour growth. Single drug administratio...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5597078</comments>
            <pubDate>Mon, 03 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5597078</guid>        </item>
        <item>
            <title>Editorial Board/Aims &amp; Scope</title>
            <link>http://www.medworm.com/index.php?rid=5304153&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS136883751100830X%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: Oral Oncology)</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5304153</comments>
            <pubDate>Sat, 01 Oct 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5304153</guid>        </item>
        <item>
            <title>Type I and III collagen degradation products in serum predict patient survival in head and neck squamous cell carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=5638244&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511008177%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Cancer invasion induces extracellular matrix remodeling and collagen degradation. The aim of this study was to assess whether serum levels of type I and III collagen degradation products were associated with patient survival in head and neck squamous cell carcinoma (HNSCC). A novel enzyme immunoassay was developed for measuring type III collagen N-terminal telopeptide (IIINTP) in human serum samples. In addition, type I collagen C-terminal telopeptide (ICTP), matrix metalloprotease-8 (MMP-8) and tissue inhibitor of metalloproteases-1 (TIMP-1) were assessed in 205 blood samples from HNSCC patients. High levels of serum ICTP and IIINTP and plasma TIMP-1 were associated with poor survival. The concentration of ICTP was associated with levels of IIINTP and TIMP-1. The plasma concentra...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5638244</comments>
            <pubDate>Mon, 26 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5638244</guid>        </item>
        <item>
            <title>A high HIF-1α expression genotype is associated with poor prognosis of upper aerodigestive tract carcinoma patients</title>
            <link>http://www.medworm.com/index.php?rid=5638243&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511008128%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: The aim of the present study was to evaluate the role of HIF-1α genetic polymorphisms and protein expression in the development of metastasis in upper aerodigestive tract cancer (UADTC) patients. The expression of pro-angiogenic markers was also evaluated. Protein expression was analysed using immunohistochemistry, and RFLP analysis was used to investigate HIF-1α C1779T and G1790A polymorphisms in 52 patients with UADTC. Primary lesions were divided into 2 groups according to the absence or presence of metastasis. Lymph node samples were divided into 3 groups: metastatic lymph nodes, non-metastatic lymph nodes (both derived from patients with metastatic disease), and control lymph nodes, which were obtained from patients without any metastasis. The allele T was more frequently f...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5638243</comments>
            <pubDate>Mon, 26 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5638243</guid>        </item>
        <item>
            <title>Common genetic mutations in the start codon of the SDH subunit D gene among Chinese families with familial head and neck paragangliomas</title>
            <link>http://www.medworm.com/index.php?rid=5638242&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511008141%2Fabstract%3Frss%3Dyes</link>
            <description>This study demonstrates that two mis-sense mutations at the start codon of the SDHD gene, including p.Met1Val (c.1A&gt;G) and p.Met1Ile (c.3G&gt;C), might be mutation hotspots in Chinese patients with familial HNPGLs. (Source: Oral Oncology)</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5638242</comments>
            <pubDate>Mon, 26 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5638242</guid>        </item>
        <item>
            <title>Sonic hedgehog signaling promotes growth of oral squamous cell carcinoma cells associated with bone destruction</title>
            <link>http://www.medworm.com/index.php?rid=5597076&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511008153%2Fabstract%3Frss%3Dyes</link>
            <description>In this study we show that the use of siRNA for Shh to block SHH secreted by SAS oral squamous cell carcinoma cells suppressed the tumor growth and tumor angiogenesis of subcutaneous SAS xenografts in vivo. Moreover, blockade of Shh in SAS cells decreased tumor growth and osteoclast number in a tibial metaphysis mouse model. Significantly, we clearly show that SHH stimulated osteoclast formation in a co-culture system consisting of murine bone stromal ST2 cells and murine CD11b+ bone marrow cells. These findings suggest that Shh signaling is a potential target for the treatment of oral squamous cell carcinoma associated with bone destruction. (Source: Oral Oncology)</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5597076</comments>
            <pubDate>Mon, 26 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5597076</guid>        </item>
        <item>
            <title>Complex cannibalism: An unusual finding in oral squamous cell carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=5638255&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511008025%2Fabstract%3Frss%3Dyes</link>
            <description>Cellular cannibalism, defined as a large cell enclosing a slightly smaller one within its cytoplasm is a characteristic morphologic feature exclusively seen in aggressive malignancies. It was first described by Leyden in 1904 and he called them ‘‘bird-eye cells’’. They were also called as ‘‘signet-ring cells”, owing to their appearance. This phenomenon of “tumor cell within a tumor cell” is frequently seen in vivo in different types of cancers; it has, for instance, been referred to as “cellular phagocytosis”, “cell phagocytosis”, “cell in cell appearance”, “cell in cell pattern”, “one cell delicately wrapped around the next”, “phagocytosis of tumor cell by tumor cell”, and “tumor cell embraced by another tumor cell”. The fact, although often i...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5638255</comments>
            <pubDate>Thu, 22 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5638255</guid>        </item>
        <item>
            <title>Association of laser phototherapy with PRP improves healing of bisphosphonate-related osteonecrosis of the jaws in cancer patients: A preliminary study</title>
            <link>http://www.medworm.com/index.php?rid=5597081&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007974%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: The aim of this study was to compare retrospectively the effect of three different treatments on the healing outcome of bisphosphonate-related osteonecrosis of the jaws (BRONJ) in cancer patients. Twenty-two cancer patients were treated for BRONJ with one of the following protocols: clinical (pharmacological therapy), surgical (pharmacological plus surgical therapy), or PRP plus LPT (pharmacological plus surgical plus platelet rich plasma (PRP) plus laser phototherapy (LPT). The laser treatment was applied with a continuous diode laser (InGaAlP, 660nm) using punctual and contact mode, 40mW, spot size 0.042 cm2, 6J/cm2 (6s) and total energy of 0.24J per point. The irradiations were performed on the exposed bone and surrounding soft tissue. The analysis of demographic data and risk ...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5597081</comments>
            <pubDate>Thu, 22 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5597081</guid>        </item>
        <item>
            <title>Radiation-associated head and neck sarcomas: Spectrum of imaging findings</title>
            <link>http://www.medworm.com/index.php?rid=5638247&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511008062%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Sarcomas developing after radiation treatment for primary malignancies of the head and neck are often detected clinically when they are very aggressive. We reviewed the patient demographics and imaging findings in 21 patients with radiation-associated sarcomas (RAS) of the head and neck treated at our institution.Twenty-one RAS of the head and neck were retrospectively reviewed. The lesions were assessed for presence of a soft tissue mass, enhancement pattern, bone destruction, characteristics of tumor matrix, and FDG avidity.The RAS developed 4.5–25years (mean 12.7years) after irradiation. On both CT and MRI, all 21 lesions presented with a soft tissue mass. A variable imaging appearance was noted on CT, MR, and PET/CT, most, but not all, demonstrated aggressive features. At a ...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5638247</comments>
            <pubDate>Wed, 21 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5638247</guid>        </item>
        <item>
            <title>Immunoexpression of p53 and hMSH2 in oral squamous cell carcinoma and oral dysplastic lesions in Yemen: Relationship to oral risk habits and prognostic factors</title>
            <link>http://www.medworm.com/index.php?rid=5638241&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS136883751100813X%2Fabstract%3Frss%3Dyes</link>
            <description>This study suggested that p53 may play a role in the early stages of oral carcinogenesis, while hMSH2 may be altered in the late stages. More importantly, the roles of p53 and hMSH2 in oral carcinogenesis seem to be interrelated in the pathogenetic pathway of oral SCC. Such a relationship has not been published previously in this type of cancer and needs to be clarified in future studies. (Source: Oral Oncology)</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5638241</comments>
            <pubDate>Wed, 21 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5638241</guid>        </item>
        <item>
            <title>The role of the adenomatous polyposis coli (APC) in oral squamous cell carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=5597077&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511008165%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: The main cause of death in oral squamous cell carcinomas (OSCC) is metastasis. Intercellular adhesion is mediated by a family of glycoproteins called cadherins and other molecules like catenins and APC (adenomatous polyposis coli) among other. The WNT (wingless-type) gene family is a group of genes, key signaling pathway for embryonic development and oncogenesis. The goal of this paper is to describe the role of the APC gene, and its derivatives, in the carcinogenicity pathway of WNT-1, identifying its role as a tumor suppressor gene in OSCC, while describing the genetic (loss of heterozygosity and mutations) and epigenetic alterations that modulate its expression and evaluate its relationship with the clinicopathological parameters of this type of tumors. As for APC, its activity...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5597077</comments>
            <pubDate>Wed, 21 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5597077</guid>        </item>
        <item>
            <title>Role of larynx-preserving partial hypopharyngectomy with and without postoperative radiotherapy for squamous cell carcinoma of the hypopharynx</title>
            <link>http://www.medworm.com/index.php?rid=5638249&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511008074%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: The purpose of this study was to examine the treatment outcomes of larynx-preserving partial hypopharyngectomies for hypopharyngeal carcinoma. Forty-three patients underwent partial hypopharyngectomy and reconstruction using faciocutaneous free flaps with and without postoperative radiotherapy between 1998 and 2009. Primary tumor sites were pyriform sinus in 35 and posterior pharyngeal wall in 8 patients. Thirty patients received postoperative radiotherapy. The 5-year overall and disease-specific survival rates were 63% and 67%, respectively. A significant positive correlation was found between pathologic N stage and primary site and disease-specific survival rates (N0/N1 stage; 93% vs. N2/N3 stage; 43%, p (Source: Oral Oncology)</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5638249</comments>
            <pubDate>Mon, 19 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5638249</guid>        </item>
        <item>
            <title>Radical radiotherapy for nasopharyngeal carcinoma in elderly patients: The importance of co-morbidity assessment</title>
            <link>http://www.medworm.com/index.php?rid=5638248&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511008086%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Elderly patients represent a unique challenge for radical treatment in nasopharyngeal carcinoma (NPC) because of age and co-morbid conditions. We sought to evaluate the outcome of this particular group of patients and to identify key factors affecting treatment outcome. From 1998 to 2008, 990 consecutive NPC patients without distant metastasis were treated with radical radiotherapy with planned total dose &gt;66Gy. Among them, 103 (10.4%) patients were elderly aged &gt;70 (group A). Their clinical characteristics and outcome were compared with those aged (Source: Oral Oncology)</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5638248</comments>
            <pubDate>Mon, 19 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5638248</guid>        </item>
        <item>
            <title>Factors influencing the outcomes of primary surgery with postoperative radiotherapy for pN2 oropharyneal squamous cell carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=5597083&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511008098%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: The purpose of this study was to examine treatment outcomes and define factors that influence survival in patients with pN2 oropharyngeal carcinoma. Fifty-five patients underwent primary surgery with postoperative radiotherapy between 1994 and 2009. Primary tumor sites were 36 tonsil, 13 base of tongue, 3 soft palate, and three posterior pharyngeal wall. There were 15, 26, 5, and 9 patients with stage T1 to T4 cancers, respectively. The N stage were 5 N2a, 37 N2b, and 13 N2c. The 5-year disease-specific survival rates were 66%. A significant positive correlation was found between high risk HPV status and extracapsular spread and disease-specific survival rates (HPV (+); 93% vs. HPV (−); 56%, p=0.031 and extracapsular spread (−); 93% vs. extracapsular spread (+); 50%, p=0.008, ...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5597083</comments>
            <pubDate>Mon, 19 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5597083</guid>        </item>
        <item>
            <title>Sentinel node biopsy for oral and oropharyngeal squamous cell carcinoma in the previously treated neck</title>
            <link>http://www.medworm.com/index.php?rid=5597082&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511008049%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: In patients with early stage oral or oropharyngeal squamous cell carcinoma (OSCC) sentinel node biopsy (SNB) is a reliable method to detect occult disease in the neck. However, patients with a history of surgery or radiotherapy in the neck may have aberrant lymphatic drainage caused by disruption of lymphatic channels. Therefore, treatment of the same levels at risk as in the primary setting may not be appropriate. The aim of our prospective observational study was to evaluate the clinical application of SNB in previously treated OSCC. Between 2003 and 2010 twenty-two patients were included. Lymph node mapping consisted of preoperative lymphoscintigraphy, SPECT/CT, intraoperative use of gamma-probe and patent blue. Endpoints were the sentinel node (SN) detection rate, unexpected l...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5597082</comments>
            <pubDate>Mon, 19 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5597082</guid>        </item>
        <item>
            <title>Secretion of IL-6 and IL-8 from lysophosphatidic acid-stimulated oral squamous cell carcinoma promotes osteoclastogenesis and bone resorption</title>
            <link>http://www.medworm.com/index.php?rid=5597075&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511008116%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Lysophosphatidic acid (LPA) is a bioactive lipid with a growth factor-like activity on a large range of cell types. Several pieces of evidence raise the possibility that LPA may play an important role in bone metastasis. Bone is a frequent metastatic site for oral cancer. However, the role of LPA in the progression of oral cancer metastasis to the bone is poorly understood. Here, we provide evidence for the role of LPA in the progression of oral cancer bone metastases and its regulatory mechanism. LPA induced the secretion of IL-6 and IL-8 in oral squamous cell carcinoma (OSCC). LPA-stimulated secretion of IL-6 and IL-8 is partly dependent on the LPA and EGF receptor (EGFR) pathways. ERK1/2 and Akt-mediated NF-κB and AP-1 were responsible for the LPA-induced IL-6 and IL-8 secreti...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5597075</comments>
            <pubDate>Mon, 19 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5597075</guid>        </item>
        <item>
            <title>Aberrant activation of Wnt/β-catenin signaling pathway contributes to the sequential progression of DMBA-induced HBP carcinomas</title>
            <link>http://www.medworm.com/index.php?rid=5597074&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007950%2Fabstract%3Frss%3Dyes</link>
            <description>In this study, we evaluated the role of β-catenin accumulation and Wnt ligands, Wnt signaling members (Fz, Dvl, APC, GSK-3β, axin, and WIF) and the downstream targets of Wnt (cyclin D1, MMP-2, and MMP-9) during the sequential progression of DMBA-induced HBP carcinomas by semi-quantitative RT-PCR and western blot analyses. Our data reveal a correlation between β-catenin accumulation and activation of Wnt signaling, and its downstream effector molecules during the sequential development of HBP carcinomas from hyperplasia to invasive carcinoma through dysplasia. Our data also support a pivotal role for β-catenin in the malignant transition of the HBP. Aberrant Wnt signaling may be a hallmark of progression to malignancy during DMBA-induced HBP carcinogenesis and could be a potential preve...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5597074</comments>
            <pubDate>Mon, 19 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5597074</guid>        </item>
        <item>
            <title>Non-invasive measurement of the microvascular properties of non-dysplastic and dysplastic oral leukoplakias by use of optical spectroscopy</title>
            <link>http://www.medworm.com/index.php?rid=5457161&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511008037%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Differential Path-length Spectroscopy (DPS) was used to non-invasively determine the optical properties of oral leukoplakias in vivo. DPS yields information on microvascular parameters such as the mucosal blood content, the microvascular blood oxygenation and the average micro-vessel diameter as well as on tissue morphological parameters such as the scattering slope and scattering amplitude. DPS measurements were made on non-dysplastic and dysplastic oral leukoplakias using a novel fiber-optic probe, and were correlated to the histological outcome of biopsies taken from the same location. Our data show borderline significant increases in mucosal blood content in dysplastic lesions compared to non-dysplastic lesions, with no changes in microvascular oxygen saturation and light scat...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5457161</comments>
            <pubDate>Wed, 14 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5457161</guid>        </item>
        <item>
            <title>Evaluation of low-level laser therapy in the prevention and treatment of radiation-induced mucositis: A double-blind randomized study in head and neck cancer patients</title>
            <link>http://www.medworm.com/index.php?rid=5457163&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511008104%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: The purpose of this prospective study was to determine the effect of the low-level laser in the prevention and treatment of mucositis in head and neck cancer patients.A total of 70 patients with malignant neoplasms in the oral cavity or oropharynx were evaluated. The patients were randomized into two low-level laser therapy groups: Group 1 (660nm/15mW/3.8J/cm2/spot size 4mm2) or Group 2 (660nm/5mW/1.3J/cm2/spot size 4mm2) starting on the first day of radiotherapy. Oral mucositis was assessed daily and weekly using the NCI and WHO scales. Oral pain was scored daily with a visual analogue scale before laser application.The patients in Group 1 had a mean time of 13.5days (range 6–26days) to present mucositis grade II, while the patients in Group 2 had a mean time of 9.8days (range ...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5457163</comments>
            <pubDate>Mon, 12 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5457163</guid>        </item>
        <item>
            <title>The volume of retropharyngeal nodes predicts distant metastasis in patients with advanced nasopharyngeal carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=5457162&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511008050%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: We investigated the effect of retropharyngeal nodal volumes (RNV) on distant metastasis in patients with advanced nasopharyngeal carcinoma (NPC). From February 2000 to June 2006, a total of 181 patients with biopsy-proven NPC, no distant metastasis, and available pre-treatment magnetic resonance imaging (MRI) were retrospectively reviewed. Most of the patients (95.6%) had stage III/IV diseases. The contour of retropharyngeal nodes ⩾5mm was delineated on the axial slides of pre-treatment T2-weighted MRI without contrast enhancement. The RNV was calculated by the Eclipse™ treatment planning software. The primary end-points were subsequent distant failure rates and distant metastasis failure-free survival (DMFFS). The pre-treatment RNV in patients who developed distant failure wa...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5457162</comments>
            <pubDate>Mon, 12 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5457162</guid>        </item>
        <item>
            <title>Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=5457158&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007822%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Tumor-infiltrating lymphocytes (TILs) are considered to represent immune reactions of the host to a malignant tumor. Programmed death receptor ligand-1 (PD-L1) is a surface protein that blocks the function of T lymphocytes and is expressed on cancer cells. Tumor-associated fibroblasts (TAFs), which influence tumor growth have also been reported to express PD-L1 and thus inhibit TILs. In the present study, we investigated the densities of CD4+/CD8+ TILs, PD-L1 expression of tumor cells and TAFs in oral squamous cell carcinoma (OSCC). Forty-five cases of OSCC were selected. We evaluated PD-L1 expression and the infiltration degree of each lymphocyte by immunohistochemical examination. These data were analyzed in connection with clinicopathological factors. Peritumoral CD8+ TILs were...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5457158</comments>
            <pubDate>Mon, 12 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5457158</guid>        </item>
        <item>
            <title>Treatment guidelines of lymphatic malformations of the head and neck</title>
            <link>http://www.medworm.com/index.php?rid=5457151&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007767%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Lymphatic malformations, traditionally called lymphangiomas, are diseases caused by development errors of the lymphatic system. About 90% of the cases occur within 2years of age, except a few cases which occur in adulthood, and approximately 75% of the lesions are located in the head and neck region. The lesions can grow rapidly with infection, trauma or bleeding, resulting in disfigurement as well as severe impairment of respiration, swallow and speech. Although lymphatic malformations are benign lesions, they rarely resolve spontaneously, their infiltrating nature coupled with the difficulty in distinguishing involved vital structures of head and neck from adjacent normal tissues makes complete surgical resection even more difficult. The likelihood of postsurgical recurrence and...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5457151</comments>
            <pubDate>Fri, 09 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5457151</guid>        </item>
        <item>
            <title>Decreased cognitive functioning in patients with advanced oral squamous cell carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=5304166&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007986%2Fabstract%3Frss%3Dyes</link>
            <description>In conclusion, this study has demonstrated the correlation of reduced cognitive functioning in patients with advanced OSCC. As a consequence, instructions for the identification of early signs and of symptoms of oral cancer are strongly recommended for relatives and nursing staff of patients with cognitive impairment. Such patients might need immediate treatment for oral cancer but might not be able to understand the significance of their symptoms and therefore present late, often too late. (Source: Oral Oncology)</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5304166</comments>
            <pubDate>Fri, 09 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5304166</guid>        </item>
        <item>
            <title>The impact of EGFR stimulation and inhibition on BPDE induced DNA fragmentation in oral/oropharyngeal mucosa in vitro</title>
            <link>http://www.medworm.com/index.php?rid=5457157&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007810%2Fabstract%3Frss%3Dyes</link>
            <description>In this study we show, that EGFR stimulation significantly decreases carcinogen induced DNA damage in normal mucosa from HNSCC patients and that this effect is completely abrogated adding an anti-EGFR antibody before stimulation, while there was no effect in non-tumor controls. The effect of EGFR inhibition was contrary. In non-tumor controls, blocking the receptor with an antibody significantly decreased DNA damage, whereas in cases no effect was seen. Our results indicate an important role of the receptor during chemical carcinogenesis. On the basis of this study we suppose, that increasing EGFR levels during head and neck carcinogenesis can be interpreted as a physiological response to permanent carcinogen impact on the mucosa. (Source: Oral Oncology)</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5457157</comments>
            <pubDate>Wed, 07 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5457157</guid>        </item>
        <item>
            <title>Nuclear translocation of MRP1 contributes to multidrug resistance of mucoepidermoid carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=5457156&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007809%2Fabstract%3Frss%3Dyes</link>
            <description>In this study, we investigated whether MRP1 was involved in the chemoresistance of mucoepidermoid carcinoma (MEC). We demonstrated that down-regulation of MRP1 in MC3/5FU, a drug-resistant MEC cell line, by RNA interference increased the drug sensitivity of the cells to 5-fluorouracil, doxorubicin, pharmorubicin, bleomycin-A5, cis-platinum and taxol. However, no significant quantitative difference of MRP1 mRNA and protein expression was found between MC3/5FU cells and its parental cell line (MC3) as determined by RT-PCR and Western blot. Interestingly, MRP1 was translocated from the cytoplasmic membrane of the MC3 cells to the nuclei of MC3/5FU cells as revealed by indirect immunofluorescence staining. Furthermore, MRP1 down-regulation mainly decreased the nuclear expression of MRP1 rather...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5457156</comments>
            <pubDate>Wed, 07 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5457156</guid>        </item>
        <item>
            <title>Hyaluronic acid–paclitaxel conjugate inhibits growth of human squamous cell carcinomas of the head and neck via a hyaluronic acid-mediated mechanism</title>
            <link>http://www.medworm.com/index.php?rid=5335294&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007706%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Chemotherapeutic regimens incorporating taxanes significantly improve outcomes for patients with squamous cell carcinomas of the head and neck (SCCHN). However, treatment with taxanes is limited by toxicities, including bone marrow suppression and peripheral neuropathies. We proposed that conjugating taxanes to targeting carrier molecules would increase antitumor efficacy and decrease toxicity. The cell surface proteoglycan, CD44, is expressed on most SCCHNs, and we hypothesized that it is an attractive candidate for targeted therapy via its natural ligand, hyaluronic acid (HA). We determined whether HA–paclitaxel conjugates were able to decrease tumor growth and improve survival in orthotopic nude mouse human SCCHN xenograft models. HA–paclitaxel concentration-dependent growt...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5335294</comments>
            <pubDate>Wed, 07 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5335294</guid>        </item>
        <item>
            <title>Clinical presentation and management of mTOR inhibitor-associated stomatitis</title>
            <link>http://www.medworm.com/index.php?rid=5304167&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007962%2Fabstract%3Frss%3Dyes</link>
            <description>The objective of this study was to report the clinical features and management outcomes of a series of cancer patients who developed painful mTOR inhibitor-associated stomatitis (mIAS). Seventeen cancer patients developed mIAS while being treated with everolimus- or ridaforolimus-containing protocols at the Dana-Farber Cancer Institute and were referred to the oral medicine clinic for evaluation and management. Clinical characteristics, toxicity management, and outcomes were summarized. In addition, the frequency and rationale for dose reductions and therapy discontinuation were assessed. The median duration of mTOR inhibitor therapy was 80days (range 9–187days). The median time to development of mouth ulcers was 10days (range 4–25days). Five patients required protocol-directed dose re...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5304167</comments>
            <pubDate>Mon, 05 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5304167</guid>        </item>
        <item>
            <title>Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer</title>
            <link>http://www.medworm.com/index.php?rid=5304160&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007755%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: We sought to identify biomarkers of antitumor activity in patients with locally advanced head and neck cancer treated with therapy containing cetuximab, an epidermal growth factor receptor (EGFR) inhibitor. Patients with stage III–IVB head and neck cancer received cisplatin, docetaxel, and cetuximab (TPE) followed by radiotherapy, cisplatin, and cetuximab (XPE) and maintenance cetuximab in a phase II clinical trial. Serum and tissue biomarkers were examined for treatment-related changes and for association with clinical outcomes. Concentrations of 31 cytokines, chemokines and growth factors were measured before and after 3 cycles (9weeks) of induction TPE using multi-analyte immunobead-based profiling (Luminex Corp., Austin, TX), with selected analytes validated by a single anal...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5304160</comments>
            <pubDate>Fri, 02 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5304160</guid>        </item>
        <item>
            <title>Co-morbidity and treatment outcomes of elderly pharyngeal cancer patients: A matched control study</title>
            <link>http://www.medworm.com/index.php?rid=5457160&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007792%2Fabstract%3Frss%3Dyes</link>
            <description>This study was aimed to asses association of co-morbidity, complications and survival in different treatment modalities of pharyngeal cancer patients.Retrospective analysis of pharyngeal cancer patients, diagnosed between 1997 and 2007 in a tertiary referral hospital was performed. Patients 75years and older (n=42), were matched with two control patients 64years and younger (n=84). Co-morbidity (ACE-27), treatment related complications and survival data were assessed and analyzed.Frequency of co-morbidity was similar in both age groups, although discarding alcohol abuse resulted in higher incidence of co-morbidity in the elderly group. Complication rate was not significantly different. In a multivariate analysis only stage found to be a significant predictor of complications. Survival esti...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5457160</comments>
            <pubDate>Thu, 01 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5457160</guid>        </item>
        <item>
            <title>Prognostic value of DNA ploidy status in patients with oral leukoplakia</title>
            <link>http://www.medworm.com/index.php?rid=5304159&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007664%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Oral leukoplakia is a potentially malignant disorder that will develop into oral cancer at an estimated rate of 1–2% per year. Aim of the present study is to assess the possible predictive value of DNA ploidy for malignant progression of oral leukoplakia.A cohort of 62 leukoplakia patients was studied and their biopsy was examined with standard histopathology and DNA image cytometry. Cox regression analysis was performed to establish the relationship between progression-free survival and the DNA ploidy status.During the follow-up time (median of 69months) 13 patients developed an oral squamous cell carcinoma (OSCC). DNA aneuploidy was observed in 27 (44%) patients and was significantly associated with a shorter progression-free survival [Hazard ratio of 3.7, 95% confidence inter...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5304159</comments>
            <pubDate>Thu, 01 Sep 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5304159</guid>        </item>
        <item>
            <title>Editorial Board/Aims &amp; Scope</title>
            <link>http://www.medworm.com/index.php?rid=5175559&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007858%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: Oral Oncology)</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5175559</comments>
            <pubDate>Tue, 30 Aug 2011 13:00:25 +0100</pubDate>
            <guid isPermaLink="false">5175559</guid>        </item>
        <item>
            <title>Factors predicting survival after diagnosis of laryngeal cancer</title>
            <link>http://www.medworm.com/index.php?rid=5457159&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007780%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Survival in patients with laryngeal cancer has not increased remarkably within the last years. It is presumed that a variety of factors act jointly in predicting survival after diagnosis: tumour stage, tumour site, treatment approaches, age and comorbidities. The aim of this German clinical multi-centre study is to present results from multivariate analysis. A retrospective cohort study was conducted in four hospitals in South–West Germany. Incident cases with laryngeal squamous cell carcinoma were included for the years 1998 to 2004, resulting in a population sample of 594 patients. Multivariate regression analysis was performed using the Cox proportional hazards model. Patients were followed up for 64.1months on average. Overall 5-year survival was 66% (95% confidence interval...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5457159</comments>
            <pubDate>Mon, 29 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5457159</guid>        </item>
        <item>
            <title>Dental implant placement after mandibular reconstruction by microvascular free fibula flap: Current knowledge and remaining questions</title>
            <link>http://www.medworm.com/index.php?rid=5457150&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007573%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Mandibular reconstruction by microvascular free fibula flap has dramatically improved the quality of life of patients treated by interruptive surgery. A simple prosthesis can be used for dental rehabilitation but in many cases, these prostheses remain nonfunctional. The use of osseointegrated implants restores both function and aesthetics.The technique for implantation in fibula flap is very similar to the technique in native mandible but access to the bone is the most difficult step of the surgery. The success rate for osteointegration ranges from 86% to 99% but the success rate of the prosthesis is much lower. This difference could be explained by the vertical discrepancy between the graft and the remaining mandible, which leads to an unfavourable implant–crown ratio. The qual...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5457150</comments>
            <pubDate>Mon, 29 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5457150</guid>        </item>
        <item>
            <title>Salivary endothelin-1 potential for detecting oral cancer in patients with oral lichen planus or oral cancer in remission</title>
            <link>http://www.medworm.com/index.php?rid=5457154&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007731%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Endothelin-1 (ET-1) is a potent vasoconstrictor involved not only in vascular biology but also in carcinogenesis. Results of a study in 2007 suggested salivary ET-1 as a potential biomarker for oral squamous cell carcinoma (OSCC), but a later study showed conflicting results. The purpose of our pilot study was to investigate feasibility of using salivary ET-1 as a biomarker for OSCC in two groups: oral lichen planus (OLP) patients and patients with OSCC in remission. Saliva samples were collected from five groups of subjects: patients with newly diagnosed, active OSCC (Group A); patients with OSCC in remission (Group B); patients with active OLP lesions (Group C); patients with OLP in remission (Group D); and normal controls (Group E). Salivary ET-1 levels were determined by enzym...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5457154</comments>
            <pubDate>Thu, 25 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5457154</guid>        </item>
        <item>
            <title>A case report of bevacizumab-related osteonecrosis of the jaw: Old problem, new culprit</title>
            <link>http://www.medworm.com/index.php?rid=5638254&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007718%2Fabstract%3Frss%3Dyes</link>
            <description>Osteonecrosis of the jaw (ONJ) is well-characterized syndrome predominantly reported in advanced stage cancer patients who had used long term bisphosphonates to treat bone metastases. Rarely, ONJ has been reported in patients who have not used bisphosphonates. Here we present an extremely rare occurrence of ONJ that occurred in a patient who received bevacizumab containing chemotherapy without bisphosphonate therapy. (Source: Oral Oncology)</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5638254</comments>
            <pubDate>Wed, 24 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5638254</guid>        </item>
        <item>
            <title>Antitumor activity of a novel histone deacetylase inhibitor (S)-HDAC42 in oral squamous cell carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=5457155&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS136883751100772X%2Fabstract%3Frss%3Dyes</link>
            <description>In this study, we investigated the antitumor effects of the novel histone deacetylase inhibitor (S)-HDAC42 in oral squamous cell carcinoma (OSCC) cells. The antiproliferative effect of (S)-HDAC42 was multifold higher than that of suberoylanilide hydroxamic acid in a panel of oral squamous carcinoma cell lines examined. (S)-HDAC42 mediated caspase-dependent apoptosis by targeting multiple signaling pathways relevant to cell cycle progression and survival. We demonstrated that (S)-HDAC42 downregulated the levels of phospho-Akt, cyclin D1, and cyclin-dependent kinase 6, accompanied by increased p27 and p21 expression. In addition, (S)-HDAC42 suppressed NF-κB signaling by blocking tumor necrosis factor-α-induced nuclear translocation, and activated reactive oxygen species generation. Finally...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5457155</comments>
            <pubDate>Wed, 24 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5457155</guid>        </item>
        <item>
            <title>Functional genetic variants of TGF-β1 and risk of tobacco-related oral carcinoma in high-risk Asian Indians</title>
            <link>http://www.medworm.com/index.php?rid=5457153&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007743%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Transforming growth factor (TGF)-β1, the most abundant isoform of TGF-β have been implicated in various stages of carcinogenesis such as epithelial to mesenchymal transition, enhanced expression of metalloproteases, down-regulation of cellular adhesion molecule, increased tumor motility and angiogenesis as well as local and systemic immunosuppression leading to a more aggressive and metastatic behavior. We assessed the association of TGF-β1 functional genetic polymorphisms at codon 10 (869 T&gt;C) and 25 (915 G&gt;C) of exon 1 in 140 patients with tobacco-related oral squamous cell carcinoma (OSCC) and 120 normal subjects by PCR–RFLP. The frequency of 869 CC genotype and C allele were significantly higher in patients as compared to controls (Pc, 0.024 and 0.0004, respectively) whil...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5457153</comments>
            <pubDate>Wed, 24 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5457153</guid>        </item>
        <item>
            <title>Perineural invasion in oral squamous cell carcinoma: A discussion of significance and review of the literature</title>
            <link>http://www.medworm.com/index.php?rid=5335289&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007779%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Perineural invasion (PNI) is a tropism of tumor cells for nerve bundles in the surrounding stroma. It is a form of tumor spread exhibited by neurotropic malignancies that correlates with aggressive behavior, disease recurrence and increased morbidity and mortality. Oral squamous cell carcinoma (OSCC) is a neurotropic malignancy that traditionally has been difficult to treat and manage. Evidence suggests that demonstration of PNI in OSCC should impact adjuvant treatment decisions and surgical management of this disease. Despite its importance as a prognostic indicator, experimental studies to explore the molecular mechanisms responsible for PNI are limited. The aim of this review is to discuss the difficulties in evaluating for PNI, review the literature regarding the relationship ...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5335289</comments>
            <pubDate>Wed, 24 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5335289</guid>        </item>
        <item>
            <title>Antitumor activity of cetuximab associated with the taxotere–cisplatin–fluorouracil (TPF) combination on an orthotopic head and neck cancer model</title>
            <link>http://www.medworm.com/index.php?rid=5304156&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS136883751100769X%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusion: The association of Cet with TPF can be considered a beneficial clinical option in advanced HN cancer patients. (Source: Oral Oncology)</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5304156</comments>
            <pubDate>Mon, 22 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5304156</guid>        </item>
        <item>
            <title>Diagnostic value of magnetic resonance lymphography in preoperative staging of clinically negative necks in squamous cell carcinoma of the oral cavity: A pilot study</title>
            <link>http://www.medworm.com/index.php?rid=5335300&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007615%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Pilot study evaluating the diagnostic value of magnetic resonance lymphography (MRL) compared with conventional imaging techniques in the preoperative staging of the clinically (palpable) negative neck (cN0) in squamous cell carcinoma of the oral cavity (SCCOC).Patients with SCCOC without clinical evidence of lymph node metastasis and scheduled for surgery underwent MRL in combination with ultrasound with or without fine needle aspiration cytology and multi-detector computer tomography. MRL images were interpreted by 2 independent radiologists. All patients were planned for resection of the primary tumor and a selective neck dissection of levels I–III. Histopathologic results were evaluated as the gold standard and compared with preoperative findings.One of nine evaluated patien...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5335300</comments>
            <pubDate>Fri, 19 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5335300</guid>        </item>
        <item>
            <title>Apicidin, a histone deaceylase inhibitor, induces both apoptosis and autophagy in human oral squamous carcinoma cells</title>
            <link>http://www.medworm.com/index.php?rid=5335293&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007688%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Apicidin acts as a potent histone deacetylases (HDAC) inhibitor and the precise mechanism for its anti-tumor activity in human oral squamous cell carcinoma (OSCC) cells has not been examined. The aim of this study was to evaluate the anti-tumor efficacy of apicidin through apoptosis and autophagy in OSCC cells. Cells were treated with apicidin and cell death was quantified. Cell cycle and apoptosis were measured using flow cytometry assay, immunoblot. Autophagy was characterized by the increase of LC3B-II and the formation of acidic vesicular organelles (AVOs). Apicidin significantly inhibited the proliferation of OSCC cells in a dose-dependent manner. Apicidin markedly up-regulated p21WAF1 led to G2/M phase arrest. Apicidin significantly increased the number of apoptotic cells co...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5335293</comments>
            <pubDate>Fri, 19 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5335293</guid>        </item>
        <item>
            <title>The impact of enteral feeding route on patient-reported long term swallowing outcome after chemoradiation for head and neck cancer</title>
            <link>http://www.medworm.com/index.php?rid=5304163&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007494%2Fabstract%3Frss%3Dyes</link>
            <description>This study explores the patients’ perspective on long-term swallowing ability comparing these two feeding routes. Two groups, receiving nutritional supplementation via a prophylactic gastrostomy tube (group G) and by the oral route or via a nasogastric tube (group NG) during CRT, disease-free at ⩾24months following treatment were matched for age, site and stage of tumour. Patient-reported swallowing outcomes for both groups were assessed using the MD Anderson Dysphagia Inventory (MDADI). Group G consisted of 16 patients and group NG of 15 patients. There was statistically significant difference in MDADI scores between the two groups in all domains of the questionnaire (p (Source: Oral Oncology)</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5304163</comments>
            <pubDate>Fri, 19 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5304163</guid>        </item>
        <item>
            <title>Head and neck specific Health Related Quality of Life scores predict subsequent survival in successfully treated head and neck cancer patients: A prospective cohort study</title>
            <link>http://www.medworm.com/index.php?rid=5304162&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007482%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: To examine the survival prediction of head and neck (H&amp;N) Health Related Quality of Life (HRQoL) scores among successfully treated and cognitive functioning H&amp;N squamous cell carcinoma (HNSCC) patients.Through structured interviews, self-reported questionnaires were given to 139 successfully treated HNSCC patients, 67±32months following diagnosis. HRQoL-scores, measured with the EORTC QLQ-H&amp;N35 inventory, self-reported levels of neuroticism, avoidance focused coping, coping by suppression of competing activity, alcohol consumption, smoking status, and heart and lung disease, as well as gender, age, TNM-stage, and tumor site were determined. The mean observation period was 75±4months among the survivors. Twenty-four deaths were observed.A EORTC QLQ-H&amp;N35 sum score, including a di...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5304162</comments>
            <pubDate>Fri, 19 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5304162</guid>        </item>
        <item>
            <title>Optimizing treatments of locally advanced squamous cell carcinoma: Where to go from here?</title>
            <link>http://www.medworm.com/index.php?rid=5304154&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007676%2Fabstract%3Frss%3Dyes</link>
            <description>As many other solid malignancies, head and neck squamous cell carcinomas (HNSCC) are a privileged field of investigations to test the efficacy of targeted therapies, both for locally advanced and recurrent/metastatic disease. In the early nineties, preclinical data first showed the impact of epidermal growth factor receptor (EGFR) inhibitors on tumor cell line and xenograft response to radiation and cytotoxic agents. At the turn of the century, various translational research studies clearly showed that (a) EGFR proteins were highly expressed in more than 90% of the patients with HNSCC, and (b) the higher the expression levels of EGFRs, the more dismal the prognosis. (Source: Oral Oncology)</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5304154</comments>
            <pubDate>Fri, 19 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5304154</guid>        </item>
        <item>
            <title>Increased risk of stroke in young head and neck cancer patients treated with radiotherapy or chemotherapy</title>
            <link>http://www.medworm.com/index.php?rid=5335302&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007652%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Young head and neck cancer patients treated with radiotherapy or chemotherapy have higher risks for stroke. Different treatment strategies should be considered in such patients. (Source: Oral Oncology)</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5335302</comments>
            <pubDate>Thu, 18 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5335302</guid>        </item>
        <item>
            <title>Distinct patterns of stomatitis with concurrent cetuximab and radiotherapy for head and neck squamous cell carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=5304164&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007640%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: To describe the distinct patterns of severe anterior stomatitis seen with concurrent cetuximab and radiotherapy (RT) compared to chemoRT or altered fractionation RT (AFRT) and explore potential associations with clinical and dosimetric parameters. We reviewed acute toxicity data from 42 patients receiving cetuximab-RT and a matched cohort of 36 patients receiving chemoRT or AFRT. The occurrence of grade ⩾3 oral toxicities was analysed with respect to clinical (age, gender, smoking/alcohol history, tumour subsite, grade of acneiform rash) and dosimetric parameters. Cetuximab-RT patients experienced higher rates of grade ⩾3 cheilitis (26% vs 6%, p=0.01) and anterior stomatitis (38% vs 6%, p=0.002), despite these structures receiving low RT doses (median maximum dose to lips 9.3G...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5304164</comments>
            <pubDate>Thu, 18 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5304164</guid>        </item>
        <item>
            <title>Juvenile psammomatoid ossifying fibroma: A review</title>
            <link>http://www.medworm.com/index.php?rid=5457152&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007548%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: In WHO classification of odontogenic tumors (2005), juvenile ossifying fibroma (JOF) is divided into juvenile psammomatoid ossifying fibroma (JPOF) and juvenile trabecular ossifying fibroma (JTOF). JPOF has been distinguished because of its location, clinical behavior, and age of occurrence. It is generally seen in younger age group and the most common site is paranasal sinuses, orbits, and fronto-ethmoidal complex. Radiologically, the internal structure can be radiolucent, mixed, or radiopaque, depending on the degree of calcification and extent of the cystic changes. Histologically, it is characterized by a densely cellular fibrous stroma interspersed with numerous psammoma bodies. The treatment is “en bloc” surgical excision while in case of intracranial extension, tumor re...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5457152</comments>
            <pubDate>Tue, 16 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5457152</guid>        </item>
        <item>
            <title>Outcome analysis of patients with well-differentiated oral cavity squamous cell carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=5335301&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007597%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: The prognosis of well-differentiated oral cavity squamous cell carcinoma (OSCC) is better than less-well-differentiated neoplasms. The aim of this retrospective study was to identify prognostic factors in patients with well-differentiated OSCC. The 5-year outcomes of 467 patients with well-differentiated OSCC who underwent radical surgery and neck dissection were analyzed. In the entire cohort, the presence of pathological node metastases (pN+ vs. pN0) was an independent predictor of 5-year outcomes. In pN0 patients, tumor depth (⩾8mm) was the only independently prognostic factor for 5-year survival rates on multivariable analysis (disease-free survival [DFS], P=0.001, hazard ratio [HR]=2.634, 95% confidence interval [95% CI]=1.496–4.636; disease-specific survival [DSS], P (So...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5335301</comments>
            <pubDate>Tue, 16 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5335301</guid>        </item>
        <item>
            <title>A novel algorithm for lymph node status prediction of oral cancer before surgery</title>
            <link>http://www.medworm.com/index.php?rid=5335298&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007585%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: An algorithm was developed to predict lymph node metastasis in patients with oral squamous cell carcinoma. To improve the diagnostic accuracy of lymph node status, we suggest a criterion for the prediction of lymph node status by combining clinical and molecular information. To develop a model to predict lymph node metastasis before surgery, principal component analysis (PCA) was applied. Patients were separated into a training set (n=60) and a test set (n=30), and four variables were evaluated: clinical T stage, clinical N stage, insulin-like growth factor II mRNA-binding protein 3 (IMP3), and cyclooxygenase-2 (COX2). PCA was applied to the training set to determine the weight of each variable. P score (patient score) was generated for each patient in the training set, and a cuto...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5335298</comments>
            <pubDate>Tue, 16 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5335298</guid>        </item>
        <item>
            <title>Intratumoural level of SDF-1 correlates with survival in head and neck squamous cell carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=5335297&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007627%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: The SDF-1/CXCR4 pathway has been suggested to play a role in the metastatic dissemination of various tumours. We assessed the prognostic impact of SDF-1 and CXCR4 expression in head and neck squamous cell carcinoma (HNSCC). Seventy-one HNSCC samples collected at the time of initial diagnosis were retrospectively analysed. SDF-1 and CXCR4 expression levels were measured using real-time RT-PCR and correlated to survival. After a median follow-up of 45months, 25 patients (35%) died of cancer (group D), and 46 patients (65%) were alive or dead without evidence of HSNCC evolution (group A). The median level of CXCR4 expression was 0.33 and 0.29 in groups A and D, respectively (P=0.93), showing no correlation with recurrence or survival. By contrast, the median level of SDF-1 expression...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5335297</comments>
            <pubDate>Tue, 16 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5335297</guid>        </item>
        <item>
            <title>Boron Neutron Capture Therapy (BNCT) in an oral precancer model: Therapeutic benefits and potential toxicity of a double application of BNCT with a six-week interval</title>
            <link>http://www.medworm.com/index.php?rid=5335291&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS136883751100755X%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Given the clinical relevance of locoregional recurrences in head and neck cancer, we developed a novel experimental model of premalignant tissue in the hamster cheek pouch for long-term studies and demonstrated the partial inhibitory effect of a single application of Boron Neutron Capture Therapy (BNCT) on tumor development from premalignant tissue. The aim of the present study was to evaluate the effect of a double application of BNCT with a 6week interval in terms of inhibitory effect on tumor development, toxicity and DNA synthesis. We performed a double application, 6weeks apart, of (1) BNCT mediated by boronophenylalanine (BPA-BNCT); (2) BNCT mediated by the combined application of decahydrodecaborate (GB-10) and BPA [(GB-10+BPA)-BNCT] or (3) beam-only, at RA-3 nuclear reacto...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5335291</comments>
            <pubDate>Tue, 16 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5335291</guid>        </item>
        <item>
            <title>Expression and mutation analysis of heterogeneous nuclear ribonucleoprotein G in human oral cancer</title>
            <link>http://www.medworm.com/index.php?rid=5335290&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007512%2Fabstract%3Frss%3Dyes</link>
            <description>This study suggest that genetic alterations and aberrant expression of hnRNP G occurring during oral carcinogenesis might be useful markers for the early detection of human oral cancer. (Source: Oral Oncology)</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5335290</comments>
            <pubDate>Tue, 16 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5335290</guid>        </item>
        <item>
            <title>Prospective speech outcome study in patients with soft palate reconstruction in tonsillar cancer</title>
            <link>http://www.medworm.com/index.php?rid=5304165&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007639%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: For advanced stage tonsil cancer, extensive resection of the soft palate is unavoidable. The purpose of this study is to report on the speech outcome according to the various types of defects and reconstruction techniques. This prospective study was performed on 53 patients of tonsil cancer. The postoperative speech function was evaluated for three factors: nasalance, speech intelligibility, and velopharyngeal insufficiency. Four reconstruction methods used for the soft palate defect: local flap, patch method, Gehanno method, and Denude method. Univariate analysis showed that the Denuded reconstruction technique, more than one-half of the soft palate resection, and T stage was significantly associated for nasalance, speech intelligibility, and velopharyngeal insufficiency. Multiva...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5304165</comments>
            <pubDate>Tue, 16 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5304165</guid>        </item>
        <item>
            <title>Extra-oral implants: Insertion per- or post-ablation?</title>
            <link>http://www.medworm.com/index.php?rid=5335299&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007561%2Fabstract%3Frss%3Dyes</link>
            <description>This study shows a significant higher survival rate of extra-oral implants placed during ablative surgery compared to implants in a later stage (p=0.044), thereby stressing the importance of installing extra-oral implants during the ablative surgical session. (Source: Oral Oncology)</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5335299</comments>
            <pubDate>Fri, 12 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5335299</guid>        </item>
        <item>
            <title>Long non-coding RNAs are expressed in oral mucosa and altered in oral premalignant lesions</title>
            <link>http://www.medworm.com/index.php?rid=5335296&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007445%2Fabstract%3Frss%3Dyes</link>
            <description>We describe the expression of 325 long non-coding RNAs, suggesting lncRNA expression contributes significantly to the oral transcriptome. Intriguingly, ∼60% of the detected lncRNAs show aberrant expression in oral premalignant lesions. A number of these lncRNAs have been previously associated with other human cancers. (Source: Oral Oncology)</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5335296</comments>
            <pubDate>Fri, 12 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5335296</guid>        </item>
        <item>
            <title>Relationship between epidermal growth factor receptor gene copy number and protein expression in oral cavity squamous cell carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=5597079&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007500%2Fabstract%3Frss%3Dyes</link>
            <description>This study was designed to explore the relationship between epidermal growth factor receptor (EGFR) copy number and EGFR protein expression in oral cavity squamous cell carcinoma (OSCCs) in Taiwan.A total of 160 oral cavity squamous cell carcinomas were examined for EGFR protein overexpression using immunohistochemistry and for copy number using a fluorescence in situ hybridization (FISH) assay.Overexpression and increased gene copy numbers of EGFR were found in 75 (46.88%) and 50 (31.25%) cases, respectively. The concordance rate for EGFR gene amplification and protein overexpression was 100%. EGFR overexpression was associated with a poor prognosis both in terms of disease-free survival (DFS) and overall survival (OS). On the other hand, the association between an increase in EGFR gene c...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5597079</comments>
            <pubDate>Wed, 10 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5597079</guid>        </item>
        <item>
            <title>Adjuvant radiotherapy and health-related quality of life of patients at intermediate risk of recurrence following primary surgery for oral squamous cell carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=5304161&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007263%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Controversy surrounds who should receive adjuvant radiotherapy in patients with intermediate risk of recurrence of oral squamous cell carcinoma following primary surgery. The aim of this study was to compare health-related quality of life (HRQOL) outcomes of those who received adjuvant radiotherapy to those who did not in patients at intermediate-risk of recurrence. A total of 765 oral cancer patients were treated at the Regional Maxillofacial Unit, Liverpool from 1995 to 2007. After excluding 124 patients (87 primary radiotherapy, 23 died within 90days, 14 had insufficient information for determining risk group status), 169 were low-risk, 271 intermediate-risk and 201 were high-risk. In the intermediate-risk group, 33% had adjuvant radiotherapy. Allowing for attrition, more than ...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5304161</comments>
            <pubDate>Wed, 10 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5304161</guid>        </item>
        <item>
            <title>Ameloblastomas have already been treated successfully with intralesional chemotherapy in dogs, why not in humans?</title>
            <link>http://www.medworm.com/index.php?rid=5638253&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007433%2Fabstract%3Frss%3Dyes</link>
            <description>In 2010, Kelly et al. reported treating six dogs with acanthomatous ameloblastoma using weekly or bimonthly intralesional or perilesional injections of bleomycin; all exhibited complete remission within 4months of the commencement of treatment. A seventh dog, with a non-resectable tumor, received palliative treatment with bleomycin. The dogs exhibited no apparent systemic toxicity to the drug; local side effects included exposure of bone, swelling and infection, all of which were readily managed. Kelly et al. based their investigation on that of Yoshida et al. who, in 1998, reported treating four dogs successfully with intralesional bleomycin. While, as yet, only 11 dogs have been reported as having been treated in this manner, the results are impressive. Would this therapy work in humans?...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5638253</comments>
            <pubDate>Mon, 08 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5638253</guid>        </item>
        <item>
            <title>The role of Cripto-1 in the tumorigenesis and progression of oral squamous cell carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=5335292&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007603%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Oral squamous cell carcinoma (OSCC), the most common malignancy of the oral cavity, remains a lethal disease in over 50% of cases diagnosed annually, due mostly to late detection of this cancer in its advanced stages despite the easy accessibility of the oral cavity for regular examinations. Cripto-1 is a member of the epidermal growth factor (EGF)–CFC protein family and is involved in the activation of several different signaling pathways during embryonic development and cellular transformation. Although the Cripto-1 protein is overexpressed in several human cancers including breast, colon, cervix, gastric, and pancreatic cancer, no prior study has evaluated Cripto-1 expression in OSCC. Therefore, our aims in this study were to examine Cripto-1 expression in clinical samples of...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5335292</comments>
            <pubDate>Mon, 08 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5335292</guid>        </item>
        <item>
            <title>Personalized medicine for mucositis: Bayesian networks identify unique gene clusters which predict the response to gamma-d-glutamyl-l-tryptophan (SCV-07) for the attenuation of chemoradiation-induced oral mucositis</title>
            <link>http://www.medworm.com/index.php?rid=5304158&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007421%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Gamma-d-glutamyl-l-tryptophan (SCV-07) demonstrated an overall efficacy signal in ameliorating oral mucositis (OM) in a clinical trial of head and neck cancer patients. However, not all SCV-07-treated subjects responded positively. Here we determined if specific gene clusters could discriminate between subjects who responded to SCV-07 and those who did not.Microarrays were done using peripheral blood RNA obtained at screening and on the last day of radiation from 28 subjects enrolled in the SCV-07 trial. An analytical technique was applied that relied on learned Bayesian networks to identify gene clusters which discriminated between individuals who received SCV-07 and those who received placebo, and which differentiated subjects for whom SCV-07 was an effective OM intervention fro...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5304158</comments>
            <pubDate>Mon, 08 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5304158</guid>        </item>
        <item>
            <title>Mutational analysis of PTEN/PIK3CA/AKT pathway in oral squamous cell carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=5304157&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007524%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: The phosphoinositide 3-kinase (PI3K)/v-akt murine thymoma (AKT) viral oncogene pathway is involved in regulating the signaling of multiple biological processes such as apoptosis, metabolism, cell proliferation, and cell growth. Mutations in the genes associated with the PI3K/AKT pathway including PI3K, AKT, RAS and PTEN, are infrequently found within head and neck squamous cell carcinoma and more specifically are rarely reported in oral squamous cell carcinoma (OSCC) cases. We aimed to investigate the frequency of mutations in AKT1, PTEN, PIK3CA, and RAS (K-RAS, N-RAS, H-RAS) genes in 37 cases of oral squamous cell carcinoma (OSCC). Mutational analysis of PTEN, RAS, PIK3CA and AKT genes was performed using chip-based matrix-assisted laser desorption time-of-flight (MALDI-TOF) mass...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5304157</comments>
            <pubDate>Mon, 08 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5304157</guid>        </item>
        <item>
            <title>TRB3 overexpression due to endoplasmic reticulum stress inhibits AKT kinase activation of tongue squamous cell carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=5304155&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007536%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Our investigation aims to evaluate the significance of TRB3, an endoplasmic reticulum stress (ERS)-inducible gene, and explore its relationship with AKT in oral tongue squamous cell carcinoma (OTSCC). Expression of TRB3 and phosphorylated AKT (p-AKT) in OTSCC tissues and adjacent normal tissues were assessed by RT-PCR, Western blot and immunohistochemistry assay. Correlation of TRB3 and AKT was validated by TRB3 adenovirus plasmid (Ad-TRB3) transfection and short hairpin RNA (shRNA) inhibition. The mRNA expression of TRB3 was significantly higher than adjacent noncancerous tissues by RT-PCR in 15 of 18 specimens of OTSCC (83.3%, P (Source: Oral Oncology)</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5304155</comments>
            <pubDate>Mon, 08 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5304155</guid>        </item>
        <item>
            <title>Human papillomavirus types 16 and 18 in epithelial dysplasia of oral cavity and oropharynx: A meta-analysis, 1985–2010</title>
            <link>http://www.medworm.com/index.php?rid=5335295&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007457%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Human papillomavirus (HPV) types 16 and 18 are causally related to a sub-set of oral cavity and oropharyngeal squamous cell cancers. However, a clear estimate of the prevalence of HPV-16/18 in oral cavity and oropharyngeal dysplasia (OOPD) is not available. This literature review and meta-analysis was conducted to provide a prevalence estimate for HPV-16/18 in OOPD. Twenty-two studies that reported prevalence of HPV-16 and/or 18 in 458 OOPD lesions were analyzed. Meta-analysis was used to evaluate the prevalence of HPV-16/18 and logistic regression was used for stratified analysis by age, gender, and histological grade. The overall prevalence of HPV-16/18 in OOPD lesions was 24.5% [95% confidence interval (CI), 16.4–36.7%)]. The individual prevalence for HPV-16 alone was 24.4%. ...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5335295</comments>
            <pubDate>Thu, 04 Aug 2011 04:00:00 +0100</pubDate>
            <guid isPermaLink="false">5335295</guid>        </item>
        <item>
            <title>Advances and applications of oral cancer basic research</title>
            <link>http://www.medworm.com/index.php?rid=5175562&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007275%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Cancer of the oral cavity accounts for almost 3% of cancer cases in the world. The incidence varies widely reflecting geographic differences in exposure to risk factors. The recent rise in younger age groups and females seen in many countries is of particular concern. Treatment and management of complications, locoregional recurrence and further primary tumors result in high morbidity and mortality especially when the disease is advanced stage at initial diagnosis. Progress in cancer research has provided abundant new knowledge about cellular processes and molecular biology underlying oral carcinogenesis and tumor progression. The present review attempts to summarize the current most widely-used research approaches and their application in the prevention, diagnosis, effective trea...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5175562</comments>
            <pubDate>Sun, 31 Jul 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5175562</guid>        </item>
        <item>
            <title>Impact of severe malnutrition on short-term mortality and overall survival in head and neck cancer</title>
            <link>http://www.medworm.com/index.php?rid=5175582&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS136883751100724X%2Fabstract%3Frss%3Dyes</link>
            <description>Conclusions: Severe malnutrition has an independent impact on overall survival of primary HNSCC patients. There is a clear distinction between patients with and without severe malnutrition from moment of diagnosis until 10 years after. This emphasizes the importance of identification and optimal treatment of malnutrition before, during and after cancer treatment. (Source: Oral Oncology)</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5175582</comments>
            <pubDate>Thu, 28 Jul 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5175582</guid>        </item>
        <item>
            <title>Differences in p63 expression in SCCHN tumours of different sub-sites within the oral cavity</title>
            <link>http://www.medworm.com/index.php?rid=5175573&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007251%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Squamous cell carcinoma of the head and neck, SCCHN, the sixth most common cancer in the world, comprises tumours of different anatomical sites. The overall survival is low, and there are no good prognostic or predictive markers available. The p53 homologue, p63, plays an important role in development of epithelial structures and has also been suggested to be involved in development of SCCHN. However, most studies on p63 in SCCHN have not taken into account the fact that this group of tumours is heterogeneous in terms of the particular site of origin of the cancer. Mapping and comparing p63 expression levels in tumours and corresponding clinically normal tissue in SCCHN from gingiva, tongue and tongue/floor of the mouth revealed clear differences between these regions. In normal s...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5175573</comments>
            <pubDate>Thu, 28 Jul 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5175573</guid>        </item>
        <item>
            <title>Addendum to “Clinical analysis of salivary gland tumor cases in West China in past 50years” [Oral Oncol. 44 (2) (2008) 187–192]</title>
            <link>http://www.medworm.com/index.php?rid=5175588&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS136883751100741X%2Fabstract%3Frss%3Dyes</link>
            <description>During the past 10years four articles have been published in different journals concerning cases of salivary gland tumor in West China Hospital of Stomatology, Sichuan University. The clinical data in the four articles seem to differ for certain histopathological types. After carefully reviewing the clinical data and the four related articles, and consulting the pathologists in the department of oral pathology in our hospital to discuss the inconsistencies in clinical data between the four articles, I list our explanation as follows: (Source: Oral Oncology)</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5175588</comments>
            <pubDate>Mon, 25 Jul 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5175588</guid>        </item>
        <item>
            <title>Xerostomia in children and adolescents after stem cell transplantation conditioned with total body irradiation or busulfan</title>
            <link>http://www.medworm.com/index.php?rid=5175583&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007226%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: To study salivary secretion rates and symptoms of xerostomia in children and adolescents conditioned with either radiation therapy or with chemotherapy only in the setting of hematopoietic stem cell transplantation (HSCT).Thirty patients conditioned with 10Gy single dose TBI (sTBI) and cyclophosphamide (Cy) 60mg/kg for two days and 35 conditioned busulfan (Bu) and Cy as part of the preparative regimen were included in the study. All patients were treated before 13years of age, and had survived 2–16years after HSCT. All patients were interviewed according to a standard questionnaire on symptoms of xerostomia and the unstimulated and stimulated whole salivary secretion rate was determined.The stimulated salivary secretion rates were 0.8±0.5ml/min in sTBI/Cy group compared to 1.1...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5175583</comments>
            <pubDate>Mon, 25 Jul 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5175583</guid>        </item>
        <item>
            <title>Association of −308 TNF-α promoter polymorphism with clinical aggressiveness in patients with head and neck squamous cell carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=5175578&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007238%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Genetic polymorphisms in the promoter region of the tumour necrosis factor-α (TNF-α) gene are involved in the regulation of the expression levels of its cytokine. Besides, these polymorphisms have been associated with the clinical behaviour of cancer. We investigated the −308 promoter region polymorphisms of the TNF-α gene and its association with the clinicopathological factors of a head and neck squamous cell carcinoma (HNSCC) sample. Furthermore, we analysed the impact of all the variables on the overall survival of patients. A sample of HNSCC (n=89) was evaluated. Clinicopathological factors and overall survival data were gathered. The TNF-α gene was analysed by using polymerase chain reaction–restriction fragment length polymorphism (PCR–RFLP). Data analyses were pe...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5175578</comments>
            <pubDate>Mon, 25 Jul 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5175578</guid>        </item>
        <item>
            <title>Intensity-modulated radiotherapy (IMRT)/Tomotherapy following neoadjuvant chemotherapy in stage IIB–IVA/B undifferentiated nasopharyngeal carcinomas (UCNT): A mono-institutional experience</title>
            <link>http://www.medworm.com/index.php?rid=5175581&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007160%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: To evaluate the outcome of Undifferentiated Nasopharyngeal Carcinomas (UCNT) treated with intensity-modulated radiation therapy with Simultaneous Integrated Boost (SIB), following induction chemotherapy. Between January 2006 and June 2009, 52 patients with stage II B-IVA/B UCNT were treated either with linac-IMRT or Tomotherapy. All patients were scheduled to receive three cycles of cisplatin based neoadjuvant chemotherapy. With a median follow-up of 38.5months (range 12.3–64.1), 3year overall survival (OS), disease-free survival (DFS), and DFS by T2a–2b and T3–T4-stage were 95.0%, 84.6%, 89.0%, and 78.0%, respectively. At multivariate analysis, none of the examined prognostic factors reported statistical significance. N-classification was not a significant predictive factor...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5175581</comments>
            <pubDate>Sun, 24 Jul 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5175581</guid>        </item>
        <item>
            <title>Dominant genetic aberrations and coexistent EBV infection in HIV-related oral plasmablastic lymphomas</title>
            <link>http://www.medworm.com/index.php?rid=5175577&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007196%2Fabstract%3Frss%3Dyes</link>
            <description>We present common cytogenetic features in the largest cohort of plasmablastic lymphoma (PBL) of the oral cavity published to date. This cohort included 45 patients, 32 of whom had a known HIV status, of which 31 were HIV positive. Ninety eight per cent of all PBL cases were known to be EBV positive. In line with previous studies, we found that rearrangements of the MYC gene was the most common genetic abnormality seen in 60% of cases with the immunoglobulin heavy chain (IGH) locus as a partner in 51% of cases. Additional complex genetic aberrations were frequent, in particular, an increased copy number of the CCND1 gene was seen in 41% of cases with true amplification of CCND1 in 15% of cases. Aneuploidy was also observed for the BCL6 gene in 28% of cases. Interestingly, rearrangements of ...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5175577</comments>
            <pubDate>Sun, 24 Jul 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5175577</guid>        </item>
        <item>
            <title>Editorial Board/Aims &amp; Scope</title>
            <link>http://www.medworm.com/index.php?rid=5052488&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007305%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: Oral Oncology)</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5052488</comments>
            <pubDate>Sat, 23 Jul 2011 14:59:45 +0100</pubDate>
            <guid isPermaLink="false">5052488</guid>        </item>
        <item>
            <title>Resilience and compensatory hypertrophy of minor salivary glands</title>
            <link>http://www.medworm.com/index.php?rid=5175585&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007184%2Fabstract%3Frss%3Dyes</link>
            <description>Xerostomia after head and neck radiotherapy can significantly affect quality of life of the surviving patients. Salivary glands are important normal structures needing sparing and modern radiotherapy tools such as Intensity Modulated Radiotherapy (IMRT) and Image Guided Radiotherapy (IGRT) have helped a modern day radiation oncologist to some extent in achieving this goal, while still delivering the desired dose to the intended target. Major salivary glands such as parotids and submandibular salivary glands have therefore been studied in numerous papers. As a result, we have various recommendations regarding their tolerance to radiation and techniques for their sparing. However, little is known about the tolerance or response of the minor salivary glands to radiation. (Source: Oral Oncolog...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5175585</comments>
            <pubDate>Tue, 19 Jul 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5175585</guid>        </item>
        <item>
            <title>A case of a squamous cell carcinoma of the tongue during pregnancy</title>
            <link>http://www.medworm.com/index.php?rid=5175586&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007172%2Fabstract%3Frss%3Dyes</link>
            <description>A 25-year-old female patient was referred to our hospital for an enlarging and non-healing ulcer on her tongue. She was well into her third trimester of an otherwise uneventful pregnancy when she noticed the lesion. An incisional biopsy at her local provincial hospital during her 26th week of gestation yielded a diagnosis of a squamous cell carcinoma. On examination, she presented with an ulcerative growth measuring 3.5cm by 5cm over the left latero-posterior border of her tongue, but the full extent and depth of invasion could not be ascertained radiographically in view of her pregnancy. There were no clinical evidences of cervical lymphadenopathies or other synchronous tumors to suggest the possibility of metastases. Her medical history was unremarkable and she denied smoking or drinking...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5175586</comments>
            <pubDate>Sun, 17 Jul 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5175586</guid>        </item>
        <item>
            <title>Salivary Epstein-Barr virus DNA level in patients with nasopharyngeal carcinoma following radiotherapy</title>
            <link>http://www.medworm.com/index.php?rid=5175576&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007202%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Nasopharyngeal carcinoma (NPC) is a solid tumor closely associated with Epstein-Barr virus (EBV) infection. The purpose of this investigation was to detect and quantify the EBV DNA level in salivary samples of NPC patients following treatment using real-time PCR. A total of 175 consecutive newly diagnosed NPC patients’ whole saliva samples were collected before treatment, and the EBV DNA level was measured by real-time PCR, with the primers and probe targeting the BamHI-W region of the EBV genome. The post-treatment salivary EBV DNA level was also assessed in 46 patients. The change of EBV DNA level before and after treatment and relationship of EBV DNA level to demographic data and tumor staging were tested by Wilcoxon signed-rank test and Mann–Whitney U test, respectively wi...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5175576</comments>
            <pubDate>Sun, 17 Jul 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5175576</guid>        </item>
        <item>
            <title>Podoplanin expression predicts prognosis in patients with oral squamous cell carcinoma treated with neoadjuvant radiochemotherapy</title>
            <link>http://www.medworm.com/index.php?rid=5175575&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007214%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Despite new therapeutic approaches patients with advanced oral squamous cell carcinoma still have a dismal prognosis. The main factor contributing to this problem is locoregional failure due to a lack of response to treatment. Several trials have proven the effect of neoadjuvant radiochemotherapy followed by radical surgery in comparison to primary surgery followed by adjuvant radiochemotherapy. No reliable parameters have been identified so far to predict response to radiochemotherapy. The aim of our study was to assess whether podoplanin expression in pretreatment biopsies could serve as a biomarker to predict the host response to neoadjuvant radiochemotherapy.In this retrospective study, podoplanin expression was examined in a set of 63 patients with oral squamous cell carcinom...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5175575</comments>
            <pubDate>Sun, 17 Jul 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5175575</guid>        </item>
        <item>
            <title>Isolation and characterization of cancer stem-like side population cells in human oral cancer cells</title>
            <link>http://www.medworm.com/index.php?rid=5175572&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007147%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Recent studies suggest that cancer stem cells may be responsible for tumorigenesis and contribute to some individuals’ resistance to cancer therapy. Some studies demonstrate that side population (SP) cells isolated from diverse cancer cell lines harbor stem cell-like properties; however, there are few reports examining the role of SP cells in human oral cancer. To determine whether human oral cancer cell lines contain a SP cell fraction, we first isolated SP cells by fluorescence activated cell sorting, followed by culturing in serum-free medium (SFM) using the SCC25 tongue cancer cell line, so that SP cells were able to be propagated to maintain the CSC property. Differential expression profile of stem cell markers (ABCG2, Oct-4 and EpCAM) was examined by RT-PCR in either SP ce...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5175572</comments>
            <pubDate>Thu, 14 Jul 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5175572</guid>        </item>
        <item>
            <title>Nef from SIVmac239 decreases proliferation and migration of adenoid-cystic carcinoma cells and inhibits angiogenesis</title>
            <link>http://www.medworm.com/index.php?rid=5175571&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511007159%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: The HIV/SIV accessory protein Nef is known to down-modulate cell surface receptors that are required for virus entry such as CD4, CCR5 and CXCR4 to block lethal viral superinfection of the infected cell. The chemokine receptor CXCR4 also plays an important role in promoting cell proliferation, metastasis and tumor angiogenesis. Therefore it was of interest to evaluate if Nef can down-regulate CXCR4 in tumor cells since this could affect these critical prognostic parameters. The CXCR4-expressing cell line ACC3 that was derived from a salivary gland adenoid cystic carcinoma (ACC) of the head and neck was transfected with Nef from SIVmac239 and cell surface expression of the receptor was monitored by FACS analysis. Real time proliferation of cells was measured with the xCELLigence sy...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5175571</comments>
            <pubDate>Thu, 14 Jul 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5175571</guid>        </item>
        <item>
            <title>Polymorphisms in tobacco metabolism and DNA repair genes modulate oral precancer and cancer risk</title>
            <link>http://www.medworm.com/index.php?rid=5175574&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511002211%2Fabstract%3Frss%3Dyes</link>
            <description>We report that genetic variants associated with premalignant and malignant conditions of the oral cavity differ. The associations appeared to be consistent among smokeless tobacco users, a characteristic risk factor in these parts. (Source: Oral Oncology)</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5175574</comments>
            <pubDate>Sun, 10 Jul 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5175574</guid>        </item>
        <item>
            <title>Established and novel NF-κB inhibitors lead to downregulation of TLR3 and the proliferation and cytokine secretion in HNSCC</title>
            <link>http://www.medworm.com/index.php?rid=5175567&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511002041%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: The transcriptional activation of NF-κB signalling has been identified as a major pathway involved in inflammation and tumor aggressiveness in a number of human cancers.Here we identify the impact of miscellaneous known and so far unknown NF-κB inhibitors originating from different drug classes on the function and proliferation of HNSCC. In detail: HNSCC cell lines were exposed to Acetylsalicylic Acid (ASA), Celecoxib, Dexamethasone, Curcumin and EPs 7630. Our major interest was to detect upstream alterations in cell signalling after applying NF-κB inhibiting substances. The inhibition of NF-κB signalling leads to an upstream regulation of Toll-like-receptor 3 (TLR3), a predominant receptor driving cell expansion. We find a marked downregulation of TLR3 and IKK complex, docume...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5175567</comments>
            <pubDate>Sun, 10 Jul 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5175567</guid>        </item>
        <item>
            <title>Ossifying fibroma of the jaws: Report of two cases and literature review</title>
            <link>http://www.medworm.com/index.php?rid=5175565&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS136883751100220X%2Fabstract%3Frss%3Dyes</link>
            <description>We present here two cases of ossifying fibroma of the jaws along with insight into the literature review. (Source: Oral Oncology)</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5175565</comments>
            <pubDate>Sun, 10 Jul 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5175565</guid>        </item>
        <item>
            <title>Role of AMP-18 in oral mucositis</title>
            <link>http://www.medworm.com/index.php?rid=5175569&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511002065%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Oral mucositis (OM) is a devasting toxicity associated with cytotoxic cancer therapy. Antrum mucosal protein (AMP)-18 and a synthetic peptide surrogate, exhibit cell protective and mitogenic properties in in vitro and in vivo models of gastrointestinal epithelial cell injury. The mucosal barrier-protective effects may be mediated by AMP-18’s capacity to increase accumulation of specific tight junction (TJ) and adherens junction proteins, and also protect against their loss after injury. Here we asked if AMP peptide could protect the oral mucosa and speed healing from radiation-induced injury. We found AMP peptide prevented radiation-induced OM in a murine model. The peptide also stimulated HaCaT cell growth used to model the oral mucosa. Binding of recombinant human (rh) AMP-18 ...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5175569</comments>
            <pubDate>Wed, 06 Jul 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5175569</guid>        </item>
        <item>
            <title>A prospective randomized multicenter clinical trial of the Provox2 and Groningen Ultra Low Resistance voice prostheses in the rehabilitation of post-laryngectomy patients: A lifetime and preference study</title>
            <link>http://www.medworm.com/index.php?rid=5175579&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS136883751100131X%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: To prospectively study patients’ preference for and the lifetime of the Groningen Ultra Low Resistance (GULR) and Provox2 tracheo-esophageal shunt prosthesis (TESP, plural TESPs) in post-laryngectomy patients. Eighty post-laryngectomy patients were included in 4 oncological centers in the Netherlands. We used a repeated measures design study with 4 randomized groups in a partial cross-over design using 3 consecutive TESPs (3 intervals) in different orders. (Group 1: GULR-GULR-GULR; Group 2: GULR-GULR-Provox2; Group 3: Provox2-Provox2-GULR; and Group 4: Provox2- Provox2-Provox2). Replacement dates and reasons for replacement were monitored with questionnaires as were patients’ preferences for GULR or Provox2. A great variability of lifetime within and between groups was seen. M...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5175579</comments>
            <pubDate>Tue, 05 Jul 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5175579</guid>        </item>
        <item>
            <title>Re-feeding syndrome in head and neck – Prevention and management</title>
            <link>http://www.medworm.com/index.php?rid=5175563&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837510001922%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: “Re-feeding syndrome” is a potentially fatal, but entirely avoidable condition. It was first reported in severely malnourished prisoners in World War II. Recently interest in the topic has seen a resurgence with the increased use of artificial nutrition and improved monitoring.In 2007, the National Institute for Clinical Excellence (NICE) has produced guidelines for the prevention and management of re-feeding syndrome. These have some important differences to the previous guidelines of the Parenteral and Enteral Nutrition Group of the British Dietetic Association (PENG).The aim of this article is to review the literature on re-feeding syndrome, and present the most recent guidelines for its diagnosis, prevention and treatment. (Source: Oral Oncology)</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5175563</comments>
            <pubDate>Tue, 05 Jul 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5175563</guid>        </item>
        <item>
            <title>Thalidomide induces apoptosis in human oral squamous cell carcinoma cell line with altered expression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)</title>
            <link>http://www.medworm.com/index.php?rid=5175587&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS136883751100203X%2Fabstract%3Frss%3Dyes</link>
            <description>Thalidomide, alone or in combination with other agents, has been used successfully to treat patients with multiple myeloma, and has been extended to the treatment of patients with some solid tumors. But data about the effects of thalidomide on oral squamous cell carcinoma (OSCC) is scarce. There are studies which reported that thalidomide as a single agent had no activity in squamous head and neck cancer. However, the populations used for the evaluation of anti-tumour efficacy in these studies were advanced head and neck squamous cell carcinomas. Effects of thalidomide on such type of malignancy may be underestimated. We used in vitro approaches to investigate whether it has any prohibitory properties on OSCC cells and whether its inhibitory effect on this type of malignancy is related wit...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5175587</comments>
            <pubDate>Sun, 03 Jul 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5175587</guid>        </item>
        <item>
            <title>Impact of image-guided radiotherapy to reduce laryngeal edema following treatment for non-laryngeal and non-hypopharyngeal head and neck cancers</title>
            <link>http://www.medworm.com/index.php?rid=5175580&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511001989%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: We would like to determine the effectiveness of image-guided radiotherapy (IGRT) to reduce laryngeal edema following treatment for head and neck cancer and to assess patient perception of voice and speech after treatment. We conducted a retrospective review of 44 patients undergoing radiation for non-laryngeal and non-hypopharyngeal head and neck cancers. Endoscopic and/or mirror examinations of the larynx were performed following radiotherapy at each follow-up visit. Laryngeal edema was assessed based on the Radiation Therapy Oncology Group grading scale. Patients were also asked to rate about the voice and speech quality relative to their pre-radiotherapy status. The mean laryngeal dose was 16.3Gy (range: 11.7–45.5Gy). At a median follow-up of 14months (range: 2–31months), t...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5175580</comments>
            <pubDate>Sun, 03 Jul 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5175580</guid>        </item>
        <item>
            <title>Myofibroblasts in the stroma of oral cancer promote tumorigenesis via secretion of activin A</title>
            <link>http://www.medworm.com/index.php?rid=5175570&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511002053%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Myofibroblasts are essential during wound healing and are often found in the stroma of oral squamous cell carcinomas (OSCC). Although the molecular mechanisms by which myofibroblasts influence OSCC remain largely unknown, previous studies demonstrated that presence of myofibroblast in OSCC stroma is an important risk factor of patient’s shortened survival. Here we showed that some growth factors are produced in higher levels by tumor-associated myofibroblasts compared to tumor-associated fibroblasts, including activin A. Myofibroblast-conditioned media containing activin A significantly increased OSCC cell proliferation and tumor volume, whereas down-regulation of activin A in the conditioned media decreased proliferation. In addition, myofibroblasts induced in vitro invasion of...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5175570</comments>
            <pubDate>Sun, 03 Jul 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5175570</guid>        </item>
        <item>
            <title>Chronic exposure to cigarette smoke increases matrix metalloproteinases and Filaggrin mRNA expression in oral keratinocytes: Role of nicotine stimulation</title>
            <link>http://www.medworm.com/index.php?rid=5175568&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511002004%2Fabstract%3Frss%3Dyes</link>
            <description>In this study, the basal expression of MMP-2, MMP-9, MMP-28, and Filaggrin has been evaluated in oral keratinocytes, in order to collect information about the ability of cigarette smoke to modify the basal expression pattern of these key enzymes in the absence of evident clinical signs in the oral epithelium. MMP-2, MMP-9, MMP-28, and Filaggrin basal expression was investigated by RT-PCR in oral keratinocytes derived from smokers (n=11), non-smokers (n=11), and ex-smokers (n=6) healthy volunteers. Moreover keratinocytes from non-smokers volunteers were stimulated in vitro by a single dose administration of nicotine (10μM) in order to estimate the effect of nicotinic receptors activation on the basal expression of the studied markers. RT-PCR analysis showed that all the markers studied wer...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5175568</comments>
            <pubDate>Sun, 03 Jul 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5175568</guid>        </item>
        <item>
            <title>Recent advances in mucin immunohistochemistry in salivary gland tumors and head and neck squamous cell carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=5175564&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511002028%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: This review focuses on the immunohistochemical expression of members of the MUC-type mucin family in salivary gland tumors and head and neck squamous cell carcinomas (HNSCC). Information is available on changes in the expression levels and distribution profiles of MUC1, MUC2, MUC3, MUC4, MUC5AC, MUC5B, MUC6 and MUC7 in tumors of the salivary glands; and of MUC1, MUC2 and MUC4 in HNSCC. In salivary gland tumors the expression patterns of MUC2, MUC3, MUC5AC and MUC6 appear to be very closely correlated with the histopathological tumor type indicating their potential use to improve diagnostic accuracy in salivary gland neoplasia. Some MUC-type mucins have emerged as valuable prognostic indicators in pleomorphic adenoma, mucoepidermoid carcinoma and HNSCC. Nine antibodies directed aga...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5175564</comments>
            <pubDate>Sun, 03 Jul 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5175564</guid>        </item>
        <item>
            <title>Elective versus therapeutic neck dissection in the clinically node negative neck in early oral cavity cancers: Do we have the answer yet?</title>
            <link>http://www.medworm.com/index.php?rid=5175561&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511002077%2Fabstract%3Frss%3Dyes</link>
            <description>The management of the clinically node negative neck in early oral cancers has been the subject of much debate. There is lack of strong evidence to suggest the superiority of elective neck dissection (END) over therapeutic neck dissection. Current guidelines recommend END when the probability of occult metastasis is greater than 20%. This assumption is based on a mathematical model proposed by Weiss et al. using a computer generated software, the findings of which are unvalidated in clinical practice. In addition, there have been numerous retrospective analysis to date, some in favour of END while others consider observation a safe option. There have been attempts to resolve this issue through randomized controlled trials (RCT) as well. To date there have been four RCTs reported in literatu...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5175561</comments>
            <pubDate>Sun, 03 Jul 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5175561</guid>        </item>
        <item>
            <title>A new classification for potentially malignant disorders of the oral cavity</title>
            <link>http://www.medworm.com/index.php?rid=5175584&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511001990%2Fabstract%3Frss%3Dyes</link>
            <description>Potentially malignant disorders (PMD) of oral cavity were classified as ‘lesions’ and ‘conditions’ by WHO in 1978. It was considered that in ‘lesions’, the cancer would correspond with the site of PMD. On the other hand, in ‘conditions’, cancer may arise in any anatomical site of the oral cavity. It is now known that even the clinically ‘normal’ appearing mucosa in patients harboring a precancerous lesion may have dysplasia on the contralateral anatomic site or molecular aberrations in other oral mucosal sites suggestive of a pathway to malignant transformation, and that cancer could subsequently arise in apparently normal tissue. Hence, the current Working Group (WHO) does not favor such subdivisions and refers to all the clinical presentations that carry the risk of o...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5175584</comments>
            <pubDate>Wed, 29 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5175584</guid>        </item>
        <item>
            <title>USC-HN2, a new model cell line for recurrent oral cavity squamous cell carcinoma with immunosuppressive characteristics</title>
            <link>http://www.medworm.com/index.php?rid=5175566&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511001928%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Head and neck squamous cell carcinomas (HNSCC) are common and aggressive tumors that have not seen an improvement in survival rates in decades. These tumors are believed to evade the immune system through a variety of mechanisms and are therefore highly immune modulatory. In order to elucidate their interaction with the immune system and develop new therapies targeting immune escape, new pre-clinical models are needed.A novel human cell line, USC-HN2, was established from a patient biopsy specimen of invasive, recurrent buccal HNSCC and characterized by morphology, heterotransplantation, cytogenetics, phenotype, gene expression, and immune modulation studies and compared to a similar HNSCC cell line; SCCL-MT1.Characterization studies confirmed the HNSCC origin of USC-HN2 and demon...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5175566</comments>
            <pubDate>Wed, 29 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5175566</guid>        </item>
        <item>
            <title>Editorial Board/Aims &amp; Scope</title>
            <link>http://www.medworm.com/index.php?rid=4970041&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511002107%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: Oral Oncology)</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4970041</comments>
            <pubDate>Mon, 27 Jun 2011 16:49:09 +0100</pubDate>
            <guid isPermaLink="false">4970041</guid>        </item>
        <item>
            <title>Phase I clinical trial of nasopharyngeal radiotherapy and concurrent celecoxib for patients with locoregionally advanced nasopharyngeal carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=5052503&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511001965%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: We evaluated the incidence of acute toxicity of concurrent cyclooxygenase-2 inhibitor (celecoxib) plus radiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma (NPC). Thirty-four patients received an accumulated radiation dose of 72–76Gy in 36–38 fractions to the primary lesion and 60Gy in 30 fractions to cervical lymph-node lesions. Palpable residual nodes were boosted to 70Gy at the 90% isodose level with an electron field. Celecoxib was administered at escalating doses of 400, 600, and 800mg/day, starting 3days before the first fraction of radiotherapy and continuing throughout the course of radiotherapy. The majority of toxicities were grade 1, with mucositis and weight loss most frequently observed (28 of 34, 82.4%), followed by dermatitis (27 of 34,...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5052503</comments>
            <pubDate>Sun, 26 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5052503</guid>        </item>
        <item>
            <title>Natural course and tumor doubling time of nasopharyngeal carcinoma. A study of 15 patients</title>
            <link>http://www.medworm.com/index.php?rid=5052501&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511001953%2Fabstract%3Frss%3Dyes</link>
            <description>This study is the first to describe and analyze the natural progression of NPC based on clinical information and calculate the tumor growth rate of NPC.Fifteen NPC patients who refused treatment after initial work-up and then subsequent re-presentation at a later time were recruited during the period from January 2003 to August 2009. Clinical data were analyzed and CT scans were used to calculate the tumor volumes. The time interval between the first planning CT image and the subsequent planning CT image was used to calculate the rate of tumor growth in this group of patients. The tumor volume doubling time can be calculated by using the formula , where t is the time interval between measurements and V2 and V1 are the tumor volumes at the end and beginning of the time interval, respectivel...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5052501</comments>
            <pubDate>Sun, 26 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5052501</guid>        </item>
        <item>
            <title>Insulin-like growth factor binding protein-3, in association with IGF-1 receptor, can predict prognosis in squamous cell carcinoma of the head and neck</title>
            <link>http://www.medworm.com/index.php?rid=5052496&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511002016%2Fabstract%3Frss%3Dyes</link>
            <description>In conclusion, it is suggested that IGFBP-3 expression, in a state of co-expression with IGF-1R, can predict poor prognosis in SCCHN patients. (Source: Oral Oncology)</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5052496</comments>
            <pubDate>Sun, 26 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5052496</guid>        </item>
        <item>
            <title>Yes-associated protein promotes cell proliferation by activating Fos Related Activator-1 in oral squamous cell carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=5052492&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511001977%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: In our previous study, we established an in vitro cellular carcinogenesis model of oral squamous cell carcinoma (OSCC), including a human immortalized oral epithelial cell (HIOEC) and a cancerous cell line (HB96). Microarray analysis showed that the gene encoding Yes-associated protein (YAP) was significantly increased in HB96 cells compared with HIOEC cells. But the underlying mechanism of YAP on oncogenesis, especially its downstream targets, are still not clear. YAP expression in OSCC cell lines and tissue specimens were investigated by using real-time PCR, western blotting and immunohistochemistry staining. YAP put-back plasmid with four mutation sites after YAP-siRNA interference was constructed by site-directed mutagenesis. Cell growth and colony formation were observed afte...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5052492</comments>
            <pubDate>Sun, 26 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5052492</guid>        </item>
        <item>
            <title>What real influence does the proto-oncogene c-myc have in OSCC behavior?</title>
            <link>http://www.medworm.com/index.php?rid=5052491&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS136883751100193X%2Fabstract%3Frss%3Dyes</link>
            <description>Abstract: The influence of c-myc in the carcinogenic process has been previously described although in the specific case of oral tumors it has been poorly tested. Myc proteins are a family of proto-oncogenes involved in the cell proliferation regulation, differentiation and apoptosis. The goal of this paper is to describe the functions of c-myc and its role as oncogene, assessing its expression by immunohistochemistry and genetic amplification studies, and studying its relationship with tumoral clinical and pathological variables, and describing genetic and molecular interactions in OSCC. (Source: Oral Oncology)</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5052491</comments>
            <pubDate>Sun, 26 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5052491</guid>        </item>
        <item>
            <title>Plasma levels of vascular endothelial growth factor during and after radiotherapy in combination with celecoxib in patients with advanced head and neck cancer</title>
            <link>http://www.medworm.com/index.php?rid=5052505&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511001862%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Celebrex and radiotherapy in advanced head and neck cancer. This phase I dose-escalation study seeks to determine the phase II recommended dose of cyclooxygenase type 2 (COX-2) inhibitor in patients with locally advanced squamous cell head and neck (H&amp;N) cancer, treated with accelerated radiotherapy. Anti-vasculogenic effect of this treatment on serum vascular endothelial growth factor (VEGF) is examined. Patients were irradiated with curative intent (72Gy in 6weeks). Celecoxib was administered throughout the radiotherapy course. Serum VEGF level were tested during radiotherapy and in follow-up. Tumor specimens were stained to quantify the COX-2 expression. Thirty-two patients completed the treatment. The dose of celecoxib was escalated (200, 400 and 800mg bid, then de-escalated t...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5052505</comments>
            <pubDate>Tue, 21 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5052505</guid>        </item>
        <item>
            <title>Prognostic significance of tumor-related genes hypermethylation detected in cancer-free surgical margins of oral squamous cell carcinomas</title>
            <link>http://www.medworm.com/index.php?rid=5052494&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511001916%2Fabstract%3Frss%3Dyes</link>
            <description>The objective of our study was to determine correlation of tumor-related genes hypermethylation detected in histopathologically negative surgical margins with clinical and prognostic parameters. The genes selected for methylation analysis covered a wide range cellular processes including cell cycle control (p16), apoptosis (DAPK and RASSF1A), Wnt signaling (APC, WIF1 and RUNX3), cell–cell adhesion (E-cad), and DNA repair (MGMT and hMLH1). All of 47 patients had histologically confirmed negative surgical margins. For each of patient, samples from primary malignant tissue and the two consecutive surgical margins were taken at the time of surgery. DNA methylation was determined by multiplex nested methylation-specific PCR. Twenty-seven patients were margin-positive for promoter hypermethyla...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5052494</comments>
            <pubDate>Tue, 21 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5052494</guid>        </item>
        <item>
            <title>The impact of late treatment-toxicity on generic health-related quality of life in head and neck cancer patients after radiotherapy</title>
            <link>http://www.medworm.com/index.php?rid=5052506&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511001898%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: To examine the impact of late treatment-related xerostomia and dysphagia on health-related quality of life (HRQOL) in head and neck cancer (HNC) patients after radiotherapy. A multi-center cross-sectional survey was performed. Patients with a follow-up of at least 6months after curative radiotherapy, without evidence of recurrent disease were eligible for inclusion. The Euroqol-5D questionnaire (EQ-5D) was filled out and toxicity was scored and converted to the RTOG scale. The EQ-5D measures generic HRQOL in terms of utility and visual analogue scale (VAS) scores. Missing data on the EQ-5D were imputed using multiple imputation. HRQOL was compared between subgroups of patients with and without toxicity. Subsequently, the impact of xerostomia and dysphagia on HRQOL was analyzed usi...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5052506</comments>
            <pubDate>Sun, 19 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5052506</guid>        </item>
        <item>
            <title>Population attributable risk of tobacco and alcohol for upper aerodigestive tract cancer</title>
            <link>http://www.medworm.com/index.php?rid=5052498&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511001680%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Tobacco and alcohol are major risk factors for upper aerodigestive tract (UADT) cancer and significant variation is observed in UADT cancer rates across Europe. We have estimated the proportion of UADT cancer burden explained by tobacco and alcohol and how this varies with the incidence rates across Europe, cancer sub-site, gender and age. This should help estimate the minimum residual burden of other risk factors to UADT cancer, including human papillomavirus. We analysed 1981 UADT cancer cases and 1993 controls from the ARCAGE multicentre study. We estimated the population attributable risk (PAR) of tobacco alone, alcohol alone and their joint effect. Tobacco and alcohol together explained 73% of UADT cancer burden of which nearly 29% was explained by smoking alone, less than 1%...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5052498</comments>
            <pubDate>Sun, 19 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5052498</guid>        </item>
        <item>
            <title>Sox2 nuclear expression is closely associated with poor prognosis in patients with histologically node-negative oral tongue squamous cell carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=5052495&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511001941%2Fabstract%3Frss%3Dyes</link>
            <description>In this study, we detected the expression of Sox2 in 82 patients with histologically node-negative (pN0) OTSCC by immunohistochemistry, and evaluated its correlation with clinicopatologic factors and disease prognosis. Sox2 positive expression was detected in 62.2% patients and showed a significant association with large tumor size. Survival analysis showed that patients with Sox2 positive expression had significantly poorer overall, cancer-specific and disease-free survivals than those with Sox2 negative expression at 5years after operation (P=0.004, 0.004 and 0.001, respectively). Multivariate analysis demonstrated that Sox2 positive expression was an independent prognosticator of unfavorable overall, cancer-specific and disease-free survivals (P=0.032, 0.035 and 0.011, respectively). Ac...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5052495</comments>
            <pubDate>Sun, 19 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5052495</guid>        </item>
        <item>
            <title>Squamous cell carcinoma of the oral cavity rarely harbours oncogenic human papillomavirus</title>
            <link>http://www.medworm.com/index.php?rid=5052493&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS136883751100162X%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Although it is now well established that a significant proportion of oropharyngeal squamous cell carcinomas (SCC) harbour oncogenic human papillomavirus (HPV) sequences, the frequency with which these sequences are detected in oral SCC (excluding oropharyngeal subsites) is highly variable. In an attempt to establish the true prevalence of HPV-16 and HPV-18 subtypes in oral SCC, we screened 142 consecutive cases from a UK cohort using both conventional PCR with consensus primers and type-specific quantitative PCR (Q-PCR), while at the same time employing a rigorous protocol to avoid sample contamination. Q-PCR revealed HPV sequences in five cases; two contained HPV-16 alone, two HPV-18 alone, and one sample carried both genotypes. However, only two of these cases (both HPV-16-posit...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5052493</comments>
            <pubDate>Sun, 19 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5052493</guid>        </item>
        <item>
            <title>Pattern of cervical lymph node metastasis in tonsil cancer: Predictive factor analysis of contralateral and retropharyngeal lymph node metastasis</title>
            <link>http://www.medworm.com/index.php?rid=5052504&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511001904%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: The purpose of this study was to determine the pattern of cervical lymph node metastasis in tonsil cancer including the retropharyngeal (RPLN) nodal metastasis. Seventy-six tonsillar squamous cell carcinoma patients who underwent surgery-based treatment were retrospectively analyzed. Most patients had advanced stage (stages III and IV: 81.6%) tonsil cancer. Sixteen patients were treated with surgery only. Postoperative radiotherapy was performed to 38 patients, and chemoradiation to 22 patients. Seventy-one therapeutic neck dissections and 27 elective neck dissections were performed. Thirty-four patients underwent RPLN dissection based on the preoperative inclusion criteria. There was a statistically significant metastasis in level I or V nodes, when the ipsilateral multilevel, or...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5052504</comments>
            <pubDate>Thu, 16 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5052504</guid>        </item>
        <item>
            <title>Malignant transformation of proliferative verrucous leukoplakia to oral squamous cell carcinoma: A series of 55 cases</title>
            <link>http://www.medworm.com/index.php?rid=5052499&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511001850%2Fabstract%3Frss%3Dyes</link>
            <description>In this study, we compared clinical differences between patients with proliferative verrucous leukoplakia (PVL) who did and did not develop oral cancer. This was a retrospective study of 55 PVL cases. All patients were followed for at least 1year, with a mean follow-up of 7.53 (SD=4.18) years. The mean age of the patients was 61.69 (SD=11.76) years. There were 36 (65.5%) females and 19 (34.5%) males. Group 1 included the 28 PVL patients who did not develop oral squamous cell carcinoma (OSCC) during the period. Group 2 included the 27 PVL patients who developed at least one OSCC during the period. The latter group was subdivided into patients with PVL who developed one (Subgroup 2a; n=16) or more than one (Subgroup 2b; n=11) OSCC during follow-up. There was no statistical difference in age ...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5052499</comments>
            <pubDate>Thu, 16 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5052499</guid>        </item>
        <item>
            <title>Risk subset of the survival for nasopharyngeal carcinoma patients with bone metastases: Who will benefit from combined treatment?</title>
            <link>http://www.medworm.com/index.php?rid=5052502&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511001874%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Bone metastasis from nasopharyngeal carcinoma (NPC) is the most frequent type of distant metastasis (DM). The purpose of this study was to elucidate survival, prognostic factors, and significant of treatment in NPC patients with bone metastasis. A total of 221 patients who developed single type of DM from NPC at the first failure after primary treatment were retrospectively recruited from January 1998 to October 2000. The correlation between disease-free interval (DFI) and clinicopathologic features was assessed by the Chi-square test. Univariate and multivariate analyses of clinicopathologic variables were performed using Cox proportional hazards regression models. Actuarial survival rates were plotted against time using the Kaplan–Meier method, and log-rank testing was used to...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5052502</comments>
            <pubDate>Sun, 12 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5052502</guid>        </item>
        <item>
            <title>Significance of tumor satellite variables in reflecting the epithelial-mesenchymal transition of tongue cancer</title>
            <link>http://www.medworm.com/index.php?rid=5052497&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511001333%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: The epithelial-mesenchymal transition (EMT) is important in determining the biological behaviors and clinical prognosis of tongue cancer. However, the heterogeneous nature of the cancer populations renders clinical grading controversial. The main purpose of EMT analysis is to identify the cell population with the greatest metastatic potentials. Therefore, tumor satellites that form at the invasive front of tongue cancer may be the optimal target for EMT evaluation. From 1999 to 2002, surgical samples of 117 consecutive tongue cancer patients diagnosed and treated at the National Taiwan University Hospital were collected. EMT-related biomarkers, including E-cadherin and vimentin, were analyzed in tongue cancer specimens to verify the association with tumor satellite variables. The ...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5052497</comments>
            <pubDate>Sun, 12 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5052497</guid>        </item>
        <item>
            <title>ACR appropriateness criteria® adjuvant therapy for resected squamous cell carcinoma of the head and neck</title>
            <link>http://www.medworm.com/index.php?rid=4970043&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511001667%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Locoregional recurrence following surgical resection alone for stage III/IV head and neck cancer is common. Adjuvant radiotherapy has been shown to improve post-operative locoregional control when compared to pre-operative radiotherapy for head and neck cancers. Following surgical resection, adverse pathological features determine the need for adjuvant therapy. High-risk pathologic features include extranodal tumor spread and involved surgical margins. Other adverse pathologic features include T 3–4 tumors, perineural invasion, lymphovascular space invasion, low neck adenopathy, and multiple tumor involved cervical lymph nodes. The standard adjuvant therapies are post-operative radiation therapy or post-operative chemoradiotherapy. Post-operative chemoradiotherapy yields superio...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4970043</comments>
            <pubDate>Sun, 12 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4970043</guid>        </item>
        <item>
            <title>The value of 18F-FDG PET/CT for the detection of distant metastases in high-risk patients with head and neck squamous cell carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=4970060&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511001886%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: The aims of this study were to assess a cohort of patients with head and neck squamous cell carcinoma (HNSCC) for: (1) the prevalence of synchronous distant metastases (DM) as detected by the initial staging by using 18F-FDG PET/CT, (2) the prevalence of metachronous DM, and (3) the validity of published risk factors with special emphasis on the maximum standardized uptake value (SUV max) for the prediction of DM. Two hundred and ninety nine patients with advanced HNSCC were included. Following risk factors at the time of diagnosis and during follow-up were analyzed: advanced T/N stage, poor histological differentiation, level IV/Vb lymph nodes, primary site in the larynx/hypopharynx, and SUV max. The prevalence of DM at initial staging and during follow-up was 10% and 11%, respec...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4970060</comments>
            <pubDate>Wed, 08 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4970060</guid>        </item>
        <item>
            <title>Overexpression of thioredoxin system proteins predicts poor prognosis in patients with squamous cell carcinoma of the tongue</title>
            <link>http://www.medworm.com/index.php?rid=4970052&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511001813%2Fabstract%3Frss%3Dyes</link>
            <description>This study aimed to evaluate the expression of Trx and Trx reductase-1 (TrxR-1) and explore the potential role of these proteins in tongue squamous cell carcinoma (TSCC). Immunohistochemistry was employed to analyze the protein expression levels of Trx and TrxR-1 in 65 TSCC tissue samples and 10 normal oral mucosa samples. The results were then evaluated semiquantitatively and compared to other clinicopathological variables. Both Trx and TrxR-1 expression levels were significantly higher in TSCC tissues as compared with the 10 normal oral mucous samples (P (Source: Oral Oncology)</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4970052</comments>
            <pubDate>Tue, 07 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4970052</guid>        </item>
        <item>
            <title>Primary burning mouth syndrome in oral submucous fibrosis patients</title>
            <link>http://www.medworm.com/index.php?rid=4970065&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511001825%2Fabstract%3Frss%3Dyes</link>
            <description>Burning mouth syndrome (BMS) is characterized by burning sensation in the tongue or oral mucous membrane often associated with symptoms such as subjective dryness of the mouth, paresthesia and altered taste for which no medical or dental cause can be found. Criteria for establishing a diagnosis of “true” BMS is presence of burning sensation on clinically healthy oral mucosa in the absence of all known local and systemic etiological factors. The diagnosis of BMS is made by excluding candidal infection, xerostomia, oral galvanism, parafunctional habits such as tongue thrusting, psychological and neurological disturbances, diabetes mellitus, menopause, side effects of drug therapy, vitamin B12 deficiency, and paraneoplastic syndromes, all of which are known to cause oral burning. The situ...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4970065</comments>
            <pubDate>Sun, 05 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4970065</guid>        </item>
        <item>
            <title>Synovial sarcoma involving skull base – A retrospective analysis of diagnosis and treatment of 21 cases in one institution</title>
            <link>http://www.medworm.com/index.php?rid=4970063&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511001540%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: To retrospectively review the diagnosis and treatment outcomes of 21 diagnosed with synovial sarcoma (SS) extending to skull base region and identify prognostic factors for local recurrence and distant metastasis. The clinical and pathological records of 21 synovial sarcoma cases involving skull base treated at Department of Oral and Maxillofacial Surgery, Affiliated to Ninth People’s Hospital, Shanghai Jiao Tong University, from 2003 to 2008 were reviewed. Parameters including clinical, radiographic, histological findings, and treatment modalities were analyzed. Prognostic factors influencing overall survival, local recurrence, and metastasis were identified. Categorical variables were compared between groups for local recurrence and distant metastasis by using 2-tailed Fisher ...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4970063</comments>
            <pubDate>Sun, 05 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4970063</guid>        </item>
        <item>
            <title>Management and outcome of head and neck squamous cell carcinomas in obese patients</title>
            <link>http://www.medworm.com/index.php?rid=4970056&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS136883751100159X%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Head and neck squamous cell carcinomas are common lesions, related to chronic smoking and drinking behaviors. But in contrast to other cancers, effect of obesity on occurrence, diagnosis, treatment and prognosis of these tumors remains to date unknown. This is a retrospective review of 111 obese patients (sex ratio=6.4, median age=54.5year old), treated between 1999 and 2007. Risk factors, tumoral localization and staging (41% stage I–II) were the same as in general population. However, we found 26.1% difficult pan-endoscopies, 54% ACE-27 comorbidity scores ⩾2 and 22.5% misstaged cervical lymphadenopathy. Treatment was based upon surgery (61%) or radiotherapy–chemotherapy (39%), and 37% of patients developed complications. Median follow up (38months) and five-year overall su...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4970056</comments>
            <pubDate>Sun, 05 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4970056</guid>        </item>
        <item>
            <title>Mouth self-examination to improve oral cancer awareness and early detection in a high-risk population</title>
            <link>http://www.medworm.com/index.php?rid=4970054&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511001655%2Fabstract%3Frss%3Dyes</link>
            <description>The objective of this study was to evaluate the effectiveness of mouth self-examination (MSE) in improving the awareness of oral cancer and its risk factors as well as test its feasibility as an oral cancer-screening tool. The study was carried out in a high-risk population of 57,704 from India, of which, 34,766 individuals who have met the eligibility criteria formed the study population. MSE brochures and trained health workers were employed for the purpose of health education and cancer screening. The present study compared their efficacy to detect oral lesions. Subjects with suspicious lesions were referred to the trained oral cancer specialist for confirmation. A questionnaire to assess the awareness of oral cancer and its risk factors was developed and validated. SPSS (v.11.0) was us...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4970054</comments>
            <pubDate>Sun, 05 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4970054</guid>        </item>
        <item>
            <title>IGF-1R expression predicts clinical outcome in patients with locally advanced oral squamous cell carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=4970053&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511001801%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: To assess the expression of IGF-1R in oral cavity squamous cell carcinoma patients, to explore its relation with clinical and pathologic prognostic factors and its role in predicting clinical outcome. One hundred and thirty-one consecutive patients suffering from oral cavity squamous cell carcinoma were included in this study from July 1989 to April 2005. Follow-up was closed in May 2010. The mean follow-up for survivors was 110.26±47.42months. Patients were staged following the TNM classification. Patients in tumour stages I and II were referred to surgery. Patients in stages III–IV were referred to postoperative radiotherapy. Radiation therapy was administered up to a mean dose of 62.13±7.74Gy in 1.8–2Gy fractions. IGF-1R expression was studied by immunohistochemistry in p...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4970053</comments>
            <pubDate>Sun, 05 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4970053</guid>        </item>
        <item>
            <title>CYP26B1 is a novel candidate gene for betel quid-related oral squamous cell carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=4970050&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511001643%2Fabstract%3Frss%3Dyes</link>
            <description>This study was to investigate the role of CYP26B1, together with the use of alcohol, BQ, and cigarettes, on BQ-related OSCC. The association study (247 OSCC cases and 338 controls) was conducted to examine the possible interplay between CYP26B1 polymorphisms and alcohol, BQ, and cigarettes use. Additional gene expression was evaluated between OSCC tissue and adjacent normal tissue. The genetic polymorphism AA of CYP26B1 appeared to correlate with the risk of OSCC (OR=2.26; 95% CI, 1.35–3.80). Chewing BQ multiplicatively interacted with CYP26B1 AA to increase the OSCC risk (aOR=70.04; 95% CI, 13.62–360.11). The independent risk of OSCC was observed among BQ chewers with CYP26B1 AA, and compared with chewers with the CYP26B1 CC genotype (stratified aOR=2.88; 95% CI, 1.07–7.74). Increas...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4970050</comments>
            <pubDate>Sun, 05 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4970050</guid>        </item>
        <item>
            <title>Foxp3 expressed by tongue squamous cell carcinoma cells correlates with clinicopathologic features and overall survival in tongue squamous cell carcinoma patients</title>
            <link>http://www.medworm.com/index.php?rid=4970045&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511001576%2Fabstract%3Frss%3Dyes</link>
            <description>In this study, the expression of Foxp3 by TSCC cells was demonstrated in TSCC tissue samples and three TSCC cell lines using immunohistochemical staining, realtime-PCR and Western blotting, and its clinical significance were statistically analyzed. The immunohistochemical assay in TSCC paraffin-embedded samples showed positive staining in 48 of 81 (59.3%) cases. The expression was significantly associated with pathologic differentiation (P=0.040) and T stage (P=0.000), and furthermore, inversely associate with patient survival (P=0.021). Multivariate analysis (Cox regression) suggested that Foxp3 expression in TSCC cells was an independent prognostic indicator for TSCC (P=0.032). (Source: Oral Oncology)</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4970045</comments>
            <pubDate>Sun, 05 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4970045</guid>        </item>
        <item>
            <title>The involvement of CHD5 hypermethylation in laryngeal squamous cell carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=4970051&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511001679%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Chromodomain helicase DNA-binding protein 5 (CHD5) has been found to be a candidate tumor suppressor gene (TSG) in malignant neural tumors. In mice heterozygous for chd5 deficiency, the first tumor observed was pathological squamous cell carcinoma. More than 95% of primary laryngeal cancer is squamous cell carcinoma. Thus, we explored the expression of CHD5 in 65 patients with laryngeal squamous cell carcinoma (LSCC) using real-time PCR, immunohistochemistry and Western blotting. DNA methylation was detected using bisulfate-specific sequencing. The potential function of CHD5 was determined using MTT, apoptosis and transwell migration assays in CHD5-transfected Hep-2 cells. Our results revealed that the mRNA and protein expression levels of CHD5 in LSCC tissues were significantly l...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4970051</comments>
            <pubDate>Wed, 01 Jun 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4970051</guid>        </item>
        <item>
            <title>Editorial Board/Aims &amp; Scope</title>
            <link>http://www.medworm.com/index.php?rid=4894899&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511001710%2Fabstract%3Frss%3Dyes</link>
            <description>(Source: Oral Oncology)</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4894899</comments>
            <pubDate>Tue, 31 May 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4894899</guid>        </item>
        <item>
            <title>18FDG-PET/CT for detecting distant metastases and second primary cancers in patients with head and neck cancer. A meta-analysis</title>
            <link>http://www.medworm.com/index.php?rid=4970044&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511001618%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: We performed a meta-analysis to evaluate the role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18FDG-PET/CT) in detecting distant metastases and second primary cancers in patients with head and neck cancer (HNC) at staging. Studies about 18FDG-PET/CT for detecting distant metastases and second primary cancers in patients with HNC were systematically searched in the MEDLINE, EMBASE, and EBM Review databases from January 1, 2000 to March 1, 2011. A software called “Meta-DiSc” was used to obtain pooled estimates of sensitivity, specificity, diagnostic odds ratios, summary receiver operating characteristic curves, and Q∗ index. Twelve articles fulfilled all inclusion criteria. The pooled sensitivity, specificity, and Q∗ index estimates with 95% c...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4970044</comments>
            <pubDate>Sun, 29 May 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4970044</guid>        </item>
        <item>
            <title>Salivary gland carcinoma in Denmark 1990–2005: A national study of incidence, site and histology. Results of the Danish Head and Neck Cancer Group (DAHANCA)</title>
            <link>http://www.medworm.com/index.php?rid=4970064&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511001606%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: To describe the incidence, site and histology (WHO 2005) of salivary gland carcinomas in Denmark. Nine hundred and eighty-three patients diagnosed from 1990 to 2005 were identified from three nation-wide registries. The associated clinical data were retrospectively retrieved from patient medical records. Histological revision was performed in 886 cases (90%). Based on histological revision, 31 patients (3%) were excluded from the study leaving 952 for epidemiological analysis. The mean crude incidence in Denmark was 1.1/100,000/year. The male vs. female ratio was 0.97 and the median age was 62years. The parotid gland was the most common site (52.5%) followed by the minor salivary glands of the oral cavity (26.3%). The most frequent histological subtypes were adenoid cystic carcino...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4970064</comments>
            <pubDate>Wed, 25 May 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4970064</guid>        </item>
        <item>
            <title>A population-based study of factors associated with early versus late stage oral cavity cancer diagnoses</title>
            <link>http://www.medworm.com/index.php?rid=4970058&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511001588%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Oral cavity cancers can be detected early yet many are diagnosed with advanced disease. We assessed risk factors for advanced stage disease in a population-based study. Study population was all Ontario patients with anterior tongue or floor of mouth cancers diagnosed between 1991 and 2000 (n=2033). Data are from a retrospective chart review. Risk factors included: demographic characteristics, co-morbidity, precancerous lesions, dental status, smoking, alcohol use, and social marginalization. Multivariate regression analyses assessed independent associations while controlling for disease grade and site. Forty percent had advanced disease. Eighty-nine percent presented with symptoms and 66% were referred by a family physician. Risk factors in the tongue group were being: age ⩾80 (...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4970058</comments>
            <pubDate>Wed, 25 May 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4970058</guid>        </item>
        <item>
            <title>EMT: New signals from the invasive front</title>
            <link>http://www.medworm.com/index.php?rid=5052490&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511001564%2Fabstract%3Frss%3Dyes</link>
            <description>The epithelial-to-mesenchymal transition (EMT), a process during which cells undergo a molecular switch from a polarized, epithelial phenotype to a highly motile, non-polarized mesenchymal phenotype, is now a recognized mechanism for dispersing cells in embryos (type 1 EMT), forming fibroblasts/mesenchymal cells in injured tissue (type 2 EMT), and initiating metastasis of epithelial cancer cells (type 3 EMT). Type 3 EMT, characterized by the combined loss of E-cadherin and gain of mesenchymal markers, such as fibronectin or vimentin, plays a crucial role in tumor progression providing tumor cells with the ability to escape from the primary tumor, to migrate to distant regions, and to invade tissues. Therefore, EMT had generally been accepted as a necessary, but not sufficient, step of meta...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5052490</comments>
            <pubDate>Tue, 24 May 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">5052490</guid>        </item>
        <item>
            <title>Validity of the FACT-H&amp;N (v 4.0) among Malaysian oral cancer patients</title>
            <link>http://www.medworm.com/index.php?rid=4970059&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511001631%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: To assess the cross-sectional construct validity of the Malay-translated and cross-culturally adapted FACT-H&amp;N (v 4.0) for discriminative use in a sample of Malaysian oral cancer patients. A cross-sectional study of adults newly diagnosed with oral cancer. HRQOL data were collected using the FACT-H&amp;N (v 4.0), a global question and a supplementary set of eight questions (‘MAQ’) obtained earlier in pilot work. Of the 76 participants (61.8% female; 23.7% younger than 50), most (96.1%) had oral squamous cell carcinoma; two-thirds were in Stages III or IV. At baseline, patients’ mean FACT summary (FACT-G, FACT-H&amp;N, FACT-H&amp;N TOI, and FHNSI) and subscale (pwb, swb, ewb, fwb, and hnsc) scores were towards the higher end of the range. Equal proportions (36.8%) rated their overall HRQ...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4970059</comments>
            <pubDate>Tue, 24 May 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4970059</guid>        </item>
        <item>
            <title>Prediction of outcome of patients with oral squamous cell carcinoma using vascular invasion and the strongly positive expression of vascular endothelial growth factors</title>
            <link>http://www.medworm.com/index.php?rid=4970049&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511001539%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Vascular invasion and lymph node metastasis have been used as histopathological prognosticators of cancers including oral squamous cell carcinoma (OSCC). In addition to metastatic potential via blood vessels, tumor-induced angiogenesis might also be associated with prognosis. However, the efficacy of combined evaluation of vascular invasion and angiogenesis-associated molecules for the prognosis of OSCC remains obscure. This is also the case in lymph node metastasis and lymphovasculogenesis-associated molecules. The aim of this study was to examine factors related to prognosis to improve the accuracy of prognostic prediction of OSCC using vasculogenesis-associated markers. Ninety specimens of patients from 1991 to 2002 with previously untreated OSCC, who underwent either biopsy or...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4970049</comments>
            <pubDate>Tue, 24 May 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4970049</guid>        </item>
        <item>
            <title>Induction chemotherapy with docetaxel and cisplatin is highly effective for locally advanced nasopharyngeal carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=4970061&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511001503%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Radiotherapy (RT) with concomitant chemotherapy (CT) has improved the therapeutic outcome of patients with locally advanced nasopharyngeal carcinoma (LANC). However, the importance of induction CT before definitive therapy is still undefined. Patients (n=59) who had LANC were included in this retrospective study. They received induction CT consisting of cisplatin and docetaxel followed by definitive RT with cisplatin. The median age was 49 years (18–68). All patients were of stages II (15%), III (63%) and IV (22%). Fifty eight patients could receive 3 cycles of CT. Except one patient, there was no grade 3 or 4 toxicity during induction CT. Chemoradiotherapy could be given to 49 patients (83%). Twelve percent of patients had complete response after induction CT and this number ha...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4970061</comments>
            <pubDate>Wed, 18 May 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4970061</guid>        </item>
        <item>
            <title>Differential survival trends for patients with tonsillar, base of tongue and tongue cancer in Sweden</title>
            <link>http://www.medworm.com/index.php?rid=4970057&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511001527%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: Tonsillar, base of tongue and tongue cancer have similar anatomical and histopathological appearances but present differences in prognosis. Human papillomavirus (HPV) is a known risk factor for tonsillar and base of tongue cancer, and a survival benefit has been shown for these tumors; however, HPV prevalence in tongue cancer is low. Tonsillar, base of tongue and tongue cancer patients registered in the Swedish Cancer Registry between 1960 and 2004 were followed from the date of cancer diagnosis until death, emigration out of Sweden, or the end of a follow-up (5years since cancer diagnosis), whichever occurred first. The relative survival rate was computed as the ratio of the observed to the expected survival rate, in which the latter was inferred from the survival of the entire S...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4970057</comments>
            <pubDate>Tue, 17 May 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4970057</guid>        </item>
        <item>
            <title>Association between metabolic syndrome and oral pre-malignancy: A community- and population-based study (KCIS No. 28)</title>
            <link>http://www.medworm.com/index.php?rid=4970055&amp;cid=s_38695_6_f&amp;fid=38695&amp;url=http%3A%2F%2Fwww.oraloncology.com%2Farticle%2FPIIS1368837511001515%2Fabstract%3Frss%3Dyes</link>
            <description>Summary: To elucidate the effect of metabolic syndrome (MetS) on oral pre-malignancy (OPM) and also to examine whether the effect is independent of areca nut chewing.We enrolled a total of 79,940 subjects aged 20years or older undergoing both oral mucous examination and health check-up for MetS within the Keelung Community-based Integrated Screening program between 2003 and 2008. We identified 368 leukoplakia, 72 erythroleukoplakia, and 69 oral submucous fibrosis. The multi-variable logistic regression was used to assess the association between MetS and OPM with adjustment of age, gender, areca nut chewing, smoking, and alcohol drinking.Subjects with MetS were at increased risk for OPM (adjusted odds ratio (aOR)=1.68, 95% confidence interval (CI): 1.39–2.04) compared with those without M...</description>
            <author>Oral Oncology</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4970055</comments>
            <pubDate>Tue, 17 May 2011 23:00:00 +0100</pubDate>
            <guid isPermaLink="false">4970055</guid>        </item>
    </channel>
</rss>

